15

20

25

### SUBSTITUTED-TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS

### Background of the Invention

# Cross Reference to Related Applications

This application claims benefit of U.S. Provisional Appl. No. 60/215,585, which was filed June 30, 2000. This application is herein incorporated by reference.

## 10 Field of the Invention

The present invention relates to a method of treating or inhibiting the growth of cancerous tumour cells and associated diseases in a mammal by administering an effective amount of a substituted-triazolopyrimidine derivative and pharmaceutically acceptable salts thereof. Further, the present invention relates to a method for the treatment or prevention of (MDR) multiple drug resistance in a mammal in need thereof which method comprises adminstering to said mammal an effective amount of a substituted triazolopyrimidine derivative or a pharmaceutically acceptable salt thereof. More specifically, the present invention relates to a method of treating or inhibiting the growth of cancerous tumour cells and associated diseases in a mammal by interacting with tubulin and microtubules and promotion of microtubule polymerization which comprises administering to said mammal an effective amount of a substituted-triazolopyrimidine derivative and pharmaceutically acceptable salts thereof.

# b) Description of the Prior Art

10

15

20

25

Most of the cytostatics in use today either inhibit the formation of essential precursors for biosynthesis of DNA or block DNA polymerases or interfere with the template function of DNA because DNA was the primary target for developing therapeutic drugs for chemotherapy. Unfortunately, inhibition of the formation of essential precursors for biosynthesis of DNA or blocking DNA polymerases or interference with the template function of DNA also affects normal tissues.

Microtubules are among the cellular structures necessary for cell growth. Tubulin is the biochemical target for several anticancer drugs, which include the vinca alkaloids vincristine and vinblastine. The interaction of vincristine and vinblastine by binding to the alpha and beta-tubulin subunits interfere with the growing and shortening of the microtubules and prevents the formation of microtubules necessary for cell functions. While these compounds have efficacy in cancer chemotherapy, they also have a destabilizing effect on the microtubules which also affects rapidly proliferating normal tissues and leads to toxicity.

Paclitaxel and its semisynthetic derivative docetaxel (Taxotere®) also interfere with microtubule formation and stabilise microtubules. Paclitaxel (Taxol®),is a diterpene isolated from the bark of the Western (Pacific) yew, *Taxus brevifolia* and is representative of a new class of therapeutic agent having a taxane ring system. It was additionally found in other members of the Taxacae family including the yew of Canada (Taxus canadensis) found in Gaspesia, eastern Canada and Taxus baccata found in Europe whose needles contain paclitaxel and analogs and hence provide a renewable source of paclitaxel and derivatives. The crude extract was tested for the first time during the 1960s and its active principle was isolated in 1971 and the chemical structure identified (M.C. Wani et al, J.Am.Chem.Soc., <u>93</u>, 2325 (1971)). Further, a wide range of activity over melanoma cells, leukemia, various carcinomas, sarcomas and non-Hodgkin lymphomas as well as a

10

15

20

25

number of solid tumors in animals was shown through additional testing. Paclitaxel and its analogs have been produced by partial synthesis from 10-deacetylbaccatin III, a precursor obtained from yew needles and twigs, and by total synthesis (Holton, et al., J. Am. Chem. Soc. 116:1597-1601 (1994) and Nicolaou, et al., Nature 367:630-634 (1994)). Paclitaxel has been demonstrated to possess antineoplastic activity. More recently, it was shown that the antitumor activity of paclitaxel is due to a promotion of microtubule polymerization (Kumar, N., J. Biol. Chem. 256:10435-10441 (1981); Rowinsky, et al., J. Natl.Cancer Inst., 82:1247-1259 (1990); and Schiff, et al., Nature, 277:665-667 (1979)). Paclitaxel has now demonstrated efficacy in several human tumors in clinical trials (McGuire, et al., Ann. Int. Med., 111:273-279 (1989); Holmes, et al., J. Natl. Cancer Inst., 83:1797-1805 (1991); Kohn et al., J. Natl. Cancer Inst., 86:18-24 (1994); and A. Bicker et al., Anti-Cancer Drugs, 4,141-148 (1993)

Paclitaxel is a microtubule blocker, inhibiting mitosis by interaction with microtubules. Paclitaxel does not prevent tubulin assembly but rather accelerates tubulin polymerization and stabilizes the assembled microtubules. Paclitaxel acts in a unique way which consists in binding to microtubules, preventing their depolymerization under conditions where usually depolymerization occurred(dilution, calcium, cold and microtubules disrupting drugs). Paclitaxel blocks the cell cycle at prophase which results in an accumulation of cells in G2+M.

Accordingly, there is still a need in the art for cytotoxic agents for use in cancer therapy. In particular, there is a need for drugs which inhibit or treat the growth of tumors which have an effect similar to paclitaxel and interfere with the process of microtubule formation. Additionally, there is a need in the art for agents which accelerate tubulin polymerization and stabilize the assembled microtubules.

10

15

20

25

Accordingly, it would be advantageous to provide a method of treating or inhibiting cell proliferation, neoplastic growth and malignant tumor growth in mammals by administering compounds which have paclitaxel like anticancer activity.

Additionally, it would be advantageous to provide a method for treating or inhibiting multiple drug resistance (MDR).

Substituted triazolopyrimidine compounds of this invention are known to the art and have found use in agriculture as fungicides. The preparation of compounds of this invention and methods of preparation are disclosed in the following United States Patent Numbers: 5,593,996; 5,756,509;5,948,783; 5,981,534; 5,612,345; 5,994,360; 6,020,338; 5,985,883; 5,854,252; 5,808,066; 5,817,663; 5,955,252; 5,965,561; 5,986,135; and 5,750,766.

Compounds of this invention are also prepared according to procedures described in the following International Publication Numbers: WO98/46607; WO98/46608; WO99/48893; WO99/41255; EPO 834513A2; EPO 782997A2; EPO 550113B1; EPO 613900B1; FR2784381A1; EPO 989130A1; WO98/41496; WO94/20501; EPO 945453A1; EPO 562615A1 and EPO 562615B1.

#### Summary of the Invention

A first object of the present invention is to provide a method of treating or inhibiting the growth of cancerous tumour cells and associated diseases in a mammal by administering an effective amount of a substituted-triazolopyrimidine derivative and pharmaceutically acceptable salts thereof.

A second object of the present invention is to provide a method of treating or inhibiting the growth of cancerous tumour cells and associated diseases in a mammal in need thereof by interacting with tubulin and microtubules by promotion of microtubule polymerization which comprises administering to said mammal an effective amount of a substituted-triazolopyrimidine derivative and pharmaceutically acceptable salts thereof.

A third object of the present invention is to provide a method of treating or inhibiting the growth of cancerous tumour cells and associated diseases in a mammal in need thereof by administering to said mammal an effective amount of a compound of Formula (I):

$$R^4$$

$$\begin{array}{c}
N \\
1 \\
N \\
3 \\
N
\end{array}$$

$$\begin{array}{c}
R^1 \\
7 \\
6 \\
5 \\
N
\end{array}$$

$$R^2$$

(I)

10

15

20

5

#### wherein:

R¹ is selected from the group consisting of halogen, an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, -CN, hydroxy, halogen, carbamoyl, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, heterocyclyl, optionally substituted bicycloalkyl of 5 to 10 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH₂-may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, thiophene, optionally substituted cycloalkenyl of 5 to 10

10

15

20

25

carbon atoms in which one —CH<sub>2</sub>- may also be replaced by —O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-cycloalkyl of 3 to 8 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -SO<sub>2</sub>aryl of 6, 10 or 14 carbon atoms, -SO<sub>2</sub>cycloalkyl of 3 to 8 carbon atoms, -SO<sub>2</sub>alkyl of 1 to 12 carbon atoms, -O-aryl of 6, 10 or 14 carbon atoms, and the moiety —NR<sup>a</sup>R<sup>b</sup>;

R<sup>a</sup> is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms, in which one –CH<sub>2</sub>- may also be replaced by –O-, -S-, or –NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of 5 to 10 carbon atoms, in which one –CH<sub>2</sub>- may also be replaced by –O-, -S-, or –NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted bicycloalkyl of 5 to 10 carbon atoms, optionally substituted tricycloalkyl, haloalkyl of 1 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, heterocyclyl, benzyl, optionally substituted benzyl, cycloalkyl of 3 to 8 carbon atoms or a 3- to 6-membered heterocyclyl ring, optionally ortho-fused with an optionally substituted phenyl ring;

R<sup>b</sup> is H, an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, optionally substituted

or cycloalkyl fused;

bicycloalkyl of 5 to 10 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms in which one -CH<sub>2</sub>- may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of 5 to 10 carbon atoms in which one -CH<sub>2</sub>- may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 5 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl, -S-alkenyl, -SO<sub>2</sub>aryl of 6, 10 or 14 carbon atoms, -SO<sub>2</sub>cycloalkyl, -SO<sub>2</sub>alkyl, -O-aryl of 6, 10 or 14 carbon atoms, heterocyclyl, benzyl, optionally substituted benzyl, cycloalkyl of 3 to 8 carbon atoms or a 3- to 6-membered heterocyclyl ring, optionally ortho-fused with an optionally substituted phenyl ring; 10 RaRb together with the nitrogen atom to which each is attached represent an optionally substituted saturated or unsaturated heterocyclyl ring from 3 to 12 ring atoms in which optionally, at least one -CH2- may optionally be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms, said saturated or unsaturated heterocyclyl ring may optionally be aryl 15

R<sup>2</sup> is H, optionally substituted alkyl of 1 to 12 carbon atoms, amino, hydroxy, alkylthio of 1 to 12 carbon atoms, cyano, carbamoyl, optionally substituted alkoxy of 1 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, aryloxy, benzyloxy, thienyl, heterocyclyl or halogen;

25 R<sup>3</sup> is H, halogen, alkyl of 1 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, aryloxy, -NR<sup>c</sup>R<sup>d</sup>, benzyloxy, aralkyloxy, haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, heterocyclyl, aryl, hydroxy,

25

30

carbamoyl, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, cyano, amino, alkylamino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, or  $-N_3$ ;

R<sup>c</sup> is H, amino, optionally substituted alkyl of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms, in which one —CH<sub>2</sub>- may also be replaced by –O-, -S-, or –NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of 5 to 10 carbon atoms, in which one —CH<sub>2</sub>- may also be replaced by –O-, -S-, or –NR where R is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted bicycloalkyl of 5 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, or heterocyclyl;

 $R^d$  is H, amino, optionally substituted alkyl of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms, in which one — $CH_2$ - may also be replaced by —O-, -S-, or —NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of 5 to 10 carbon atoms, in which one — $CH_2$ - may also be replaced by —O-, -S-, or —NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted bicycloalkyl of 5 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, or heterocyclyl;

R<sup>c</sup>R<sup>d</sup> together with the nitrogen atom to which each is attached represent an optionally substituted heterocyclyl ring from 3 to 8 ring atoms optionally

15

20

25

substituted in which one  $-CH_2$ - may also be replaced by -O-, -S-, or -NR' where R' is H or alkyl of 1 to 12 carbon atoms;

R<sup>4</sup> is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkoxy of 1 to 12 carbon atoms, amino, alkyl amino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, halogen, cyano, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, heterocyclyl, halogen, carbamoyl, optionally substituted aryl of 6, 10 or 14 carbon atoms, or -CF<sub>3</sub>;

provided that when: a) R¹ is diethylamino, R³ is chloro, R⁴ is hydrogen, R² is not 4-trifluoromethylphenyl, 3,4-dichlorophenyl, 4-chlorophenyl, 3-chloro-4-methoxyphenyl; b) R¹ is diethylamino, R³ is bromo, R⁴ is hydrogen, R² is not 4-trifluoromethylphenyl; c) R¹ is isopropylamino, R³ is chloro, R⁴ is hydrogen, R² is not 2-benzyloxyphenyl or 3,4,5-trimethoxyphenyl; d) R¹ is

cyclopentylamino, R³ is chloro, R⁴ is hydrogen, R² is not 3,4,5-trimethoxyphenyl, 2-napthyl or 2-stilbene; e) R¹ is 2-aminobicyclo(2.2.1.)heptyl, R³ is chloro, R⁴ is hydrogen, R² is not 3,4,5-trimethoxyphenyl and f) R¹ is diethylamino, R³ is chloro, R⁴ is hydrogen, R² is not 4-trifluoromethylphenyl and g) R¹ is 1,1,1-trifluoroethoxy, R³ is chloro, R⁴ is hydrogen, R² is not 2-chloro-6-fluorophenyl h) R¹ is –SO₂ethyl or

-SO<sub>2</sub>cyclopentyl, R<sup>3</sup> is chloro, R<sup>4</sup> is hydrogen, R<sup>2</sup> is not 2-chloro-6-fluorophenyl; i) R<sup>4</sup> is hydrogen, R<sup>2</sup> is 2-chloro-6-fluorophenyl, R<sup>1</sup> and R<sup>3</sup> are not 1,2,4-triazole; j) R<sup>1</sup> is cyclohexyl, R<sup>4</sup> is hydrogen, R<sup>2</sup> is 2,4,6-trifluorophenyl, and R<sup>3</sup> is not

-OCH<sub>2</sub>O<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>; k) R<sup>1</sup> is 2-thienyl, R<sup>4</sup>

is ethyl,  $R^3$  is hydrogen and  $R^2$  is not 2-methoxyphenyl, 4-methoxyphenyl, and 4-trifluorophenyl; I)  $R^2$  is phenyl,  $R^3$  is chloro,  $R^4$  is hydrogen,  $R^1$  is not (2E)-,7-dimethyl-2,6-octadienyl or a pharmaceutically acceptable salt thereof.

A fourth object of the present invention is to provide a method of treating or inhibiting the growth of cancerous tumour cells and associated diseases in a mammal in need thereof by interacting with tubulin and microtubules by promotion of microtubule polymerization which comprises administering to said mammal an effective amount of a compound of Formula (I):

**(I)** 

10

15

20

wherein:

R¹ is selected from the group consisting of halogen, an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, -CN, hydroxy, halogen, carbamoyl, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, heterocyclyl, optionally substituted bicycloalkyl of 5 to 10 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH₂-may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, thiophene, optionally substituted cycloalkenyl of 5 to 10 carbon atoms in which one -CH₂- may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10

or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-cycloalkyl of 3 to 8 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -SO<sub>2</sub>aryl of 6, 10 or 14 carbon atoms, -SO<sub>2</sub>cycloalkyl of 3 to 8 carbon atoms, -SO<sub>2</sub>alkyl of 1 to 12 carbon atoms, -O-aryl of 6, 10 or 14 carbon atoms, and the moiety -NR<sup>a</sup>R<sup>b</sup>;

5

10

15

20

R<sup>a</sup> is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms, in which one –CH<sub>2</sub>- may also be replaced by –O-, -S-, or –NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of 5 to 10 carbon atoms, in which one –CH<sub>2</sub>- may also be replaced by –O-, -S-, or –NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted bicycloalkyl of 5 to 10 carbon atoms, optionally substituted tricycloalkyl, haloalkyl of 1 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, heterocyclyl, benzyl, optionally substituted benzyl, cycloalkyl of 3 to 8 carbon atoms or a 3- to 6-membered heterocyclyl ring, optionally ortho-fused with an

optionally substituted phenyl ring;

R<sup>b</sup> is H, an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, optionally substituted bicycloalkyl of 5 to 10 carbon atoms, optionally substituted cycloalkyl of 3 to

10 carbon atoms in which one –CH<sub>2</sub>- may also be replaced by –O-, -S-, or –NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of 5 to 10 carbon atoms in which one –CH<sub>2</sub>- may also be replaced by –O-, -S-, or –NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl, -S-alkenyl, -SO<sub>2</sub>aryl of 6, 10 or 14 carbon atoms, -SO<sub>2</sub>cycloalkyl, -SO<sub>2</sub>alkyl, -O-aryl of 6, 10 or 14 carbon atoms, heterocyclyl, benzyl, optionally substituted benzyl, cycloalkyl of 3 to 8 carbon atoms or a 3- to 6-membered heterocyclyl ring, optionally ortho-fused with an optionally substituted phenyl ring;

10

15

20

R<sup>a</sup>R<sup>b</sup> together with the nitrogen atom to which each is attached represent an optionally substituted saturated or unsaturated heterocyclyl ring from 3 to 12 ring atoms in which optionally, at least one —CH<sub>2</sub>- may optionally be replaced by —O-, -S-, or —NR where R is H or an alkyl group of 1 to 12 carbon atoms, said saturated or unsaturated heterocyclyl ring may optionally be aryl or cycloalkyl fused;

R<sup>2</sup> is H, optionally substituted alkyl of 1 to 12 carbon atoms, amino, hydroxy, alkylthio of 1 to 12 carbon atoms, cyano, carbamoyl, optionally substituted alkoxy of 1 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, aryloxy, benzyloxy, thienyl, heterocyclyl or halogen;

25 R<sup>3</sup> is H, halogen, alkyl of 1 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, aryloxy, -NR<sup>c</sup>R<sup>d</sup>, benzyloxy, aralkyloxy, haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, heterocyclyl, aryl, hydroxy, carbamoyl, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, cyano, amino,

alkylamino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, or  $-N_3$ ;

 $R^c$  is H, amino, optionally substituted alkyl of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms, in which one  $-CH_2$ - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of 5 to 10 carbon atoms, in which one  $-CH_2$ - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted bicycloalkyl of 5 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, heterocyclyl;

15

20

25

30

10

5

 $R^d$  is H, amino, optionally substituted alkyl of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms, in which one  $-CH_2$ - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of 5 to 10 carbon atoms, in which one  $-CH_2$ - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted bicycloalkyl of 5 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, or heterocyclyl;

R<sup>c</sup>R<sup>d</sup> together with the nitrogen atom to which each is attached represent an optionally substituted heterocyclyl ring from 3 to 8 ring atoms optionally substituted in which one –CH<sub>2</sub>- may also be replaced by –O-, -S-, or –NR' where R' is H or alkyl of 1 to 12 carbon atoms;

R<sup>4</sup> is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkoxy of 1 to 12 carbon atoms, amino, alkyl amino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, halogen, cyano, carboxy, alkoxycarbonyl of 2 to 12 carbon . 5 atoms, heterocyclyl, halogen, carbamoyl, optionally substituted aryl of 6, 10 or 14 carbon atoms, or -CF<sub>3</sub>: provided that when: a) R<sup>1</sup> is diethylamino, R<sup>3</sup> is chloro, R<sup>4</sup> is hydrogen, R<sup>2</sup> is not 4-trifluoromethylphenyl, 3,4-dichlorophenyl, 4-chlorophenyl, 3-chloro-4methoxyphenyl; b) R<sup>1</sup> is diethylamino, R<sup>3</sup> is bromo, R<sup>4</sup> is hydrogen, R<sup>2</sup> is not 10 4-trifluoromethylphenyl; c) R<sup>1</sup> is isopropylamino, R<sup>3</sup> is chloro, R<sup>4</sup> is hydrogen, R<sup>2</sup> is not 2-benzyloxyphenyl or 3,4,5-trimethoxyphenyl; d) R<sup>1</sup> is cyclopentylamino, R<sup>3</sup> is chloro, R<sup>4</sup> is hydrogen, R<sup>2</sup> is not 3,4,5trimethoxyphenyl, 2-napthyl or 2-stilbene; e) R<sup>1</sup> is 2-aminobicyclo(2.2.1.)heptyl. R<sup>3</sup> is chloro, R<sup>4</sup> is hydrogen, R<sup>2</sup> is not 3,4,5-15 trimethoxyphenyl and f) R<sup>1</sup> is diethylamino, R<sup>3</sup> is chloro, R<sup>4</sup> is hydrogen, R<sup>2</sup> is not 4-trifluoromethylphenyl and g) R<sup>1</sup> is 1,1,1-trifluoroethoxy, R<sup>3</sup> is chloro, R<sup>4</sup> is hydrogen, R<sup>2</sup> is not 2-chloro-6-fluorophenyl h) R<sup>1</sup> is -SO<sub>2</sub>ethyl or -SO<sub>2</sub>cyclopentyl, R<sup>3</sup> is chloro, R<sup>4</sup> is hydrogen, R<sup>2</sup> is not 2-chloro-6fluorophenyl; i) R<sup>4</sup> is hydrogen, R<sup>2</sup> is 2-chloro-6-fluorophenyl, R<sup>1</sup> and R<sup>3</sup> are 20 not 1,2,4-triazole; j) R<sup>1</sup> is cyclohexyl, R<sup>4</sup> is hydrogen, R<sup>2</sup> is 2,4,6trifluorophenyl, and R<sup>3</sup> is not —OCH<sub>2</sub>O<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>; k) R<sup>1</sup> is 2-thienyl, R<sup>4</sup> is ethyl, R<sup>3</sup> is hydrogen and R<sup>2</sup> is not 2-methoxyphenyl, 4-methoxyphenyl, and 4-trifluorophenyl; I) R<sup>2</sup> is phenyl, R<sup>3</sup> is chloro, R<sup>4</sup> is hydrogen R<sup>1</sup> is not (2E)-,7-dimethyl-2,6-octadienyl 25 or a pharmaceutically acceptable salt thereof.

A fifth object of the present invention is to provide a method for the treatment or prevention of multiple drug resistance (MDR) in a mammal in need thereof which method comprises administering to said mammal an effective amount of a substituted triazolopyrimidine derivative or a

pharmaceutically acceptable salt thereof. In particular the multiple drug resistance (MDR) is mediated by p-glycoprotein or MXR.

A sixth object of the present invention is to provide a method for the treatment or prevention of multiple drug reistance (MDR) in a mammal in need thereof by administering to said mammal an effective amount of a compound of Formula (I):

$$R^4$$

$$\begin{array}{c}
N \\
1 \\
N \\
3 \\
N
\end{array}$$

$$\begin{array}{c}
R^1 \\
7 \\
6 \\
4 \\
5
\end{array}$$

$$\begin{array}{c}
R^2 \\
4 \\
5
\end{array}$$

$$\begin{array}{c}
R^3 \\
\end{array}$$

**(I)** 

10

15

20

5

#### wherein:

R¹ is selected from the group consisting of halogen, an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, -CN, hydroxy, halogen, carbamoyl, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, heterocyclyl, optionally substituted bicycloalkyl of 5 to 10 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH₂-may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, thiophene, optionally substituted cycloalkenyl of 5 to 10 carbon atoms in which one -CH₂- may also be replaced by -O-, -S-, or

-NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-cycloalkyl of 3 to 8 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -SO<sub>2</sub>aryl of 6, 10 or 14 carbon atoms, -SO<sub>2</sub>cycloalkyl of 3 to 8 carbon atoms, -SO<sub>2</sub>alkyl of 1 to 12 carbon atoms, -O-aryl of 6, 10 or 14 carbon atoms, and the moiety -NR<sup>a</sup>R<sup>b</sup>;

R<sup>a</sup> is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkaynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms, in which one –CH<sub>2</sub>- may also be replaced by –O-, -S-, or –NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of 5 to 10 carbon atoms, in which one –CH<sub>2</sub>- may also be replaced by –O-, -S-, or –NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted bicycloalkyl of 5 to 10 carbon atoms, optionally substituted tricycloalkyl, haloalkyl of 1 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, heterocyclyl, benzyl, optionally substituted benzyl, cycloalkyl of 3 to 8 carbon atoms or a 3- to 6-membered heterocyclyl ring, optionally ortho-fused with an optionally substituted phenyl ring;

20

25

15

5

10

R<sup>b</sup> is H, an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, optionally substituted bicycloalkyl of 5 to 10 carbon atoms, optionally substituted cycloalkyl of 3 to

20

25

10 carbon atoms in which one –CH<sub>2</sub>- may also be replaced by –O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of 5 to 10 carbon atoms in which one –CH<sub>2</sub>- may also be replaced by –O-, -S-, or –NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl, -S-alkenyl, -SO<sub>2</sub>aryl of 6, 10 or 14 carbon atoms, -SO<sub>2</sub>cycloalkyl, -SO<sub>2</sub>alkyl, -O-aryl of 6, 10 or 14 carbon atoms, heterocyclyl, benzyl, optionally substituted benzyl, cycloalkyl of 3 to 8 carbon atoms or a 3- to 6-membered heterocyclyl ring, optionally ortho-fused with an optionally substituted phenyl ring;

10 R<sup>a</sup>R<sup>b</sup> together with the nitrogen atom to which each is attached represent an optionally substituted saturated or unsaturated heterocyclyl ring from 3 to 12 ring atoms in which optionally, at least one —CH<sub>2</sub>- may optionally be replaced by –O-, -S-, or –NR where R is H or an alkyl group of 1 to 12 carbon atoms, said saturated or unsaturated heterocyclyl ring may optionally be aryl or cycloalkyl fused;

R<sup>2</sup> is H, optionally substituted alkyl of 1 to 12 carbon atoms, amino, hydroxy, alkylthio of 1 to 12 carbon atoms, cyano, carbamoyl, optionally substituted alkoxy of 1 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, aryloxy, benzyloxy, thienyl, heterocyclyl or halogen;

R<sup>3</sup> is H, halogen, alkyl of 1 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, aryloxy, -NR<sup>c</sup>R<sup>d</sup>, benzyloxy, aralkyloxy, haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, heterocyclyl, aryl, hydroxy, carbamoyl, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, cyano, amino,

alkylamino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, or  $-N_3$ ;

R<sup>c</sup> is H, amino, optionally substituted alkyl of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms, in which one —CH<sub>2</sub>- may also be replaced by –O-, -S-, or –NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of 5 to 10 carbon atoms, in which one —CH<sub>2</sub>- may also be replaced by –O-, -S-, or –NR where R is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted bicycloalkyl of 5 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, or heterocyclyl;

15

20

25

30

5

10

R<sup>d</sup> is H, amino, optionally substituted alkyl of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms, in which one —CH<sub>2</sub>- may also be replaced by —O-, -S-, or —NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of 5 to 10 carbon atoms, in which one —CH<sub>2</sub>- may also be replaced by —O-, -S-, or —NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted bicycloalkyl of 5 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, or heterocyclyl;

R<sup>c</sup>R<sup>d</sup> together with the nitrogen atom to which each is attached represent an optionally substituted heterocyclyl ring from 3 to 8 ring atoms optionally substituted in which one –CH<sub>2</sub>- may also be replaced by –O-, -S-, or –NR' where R' is H or alkyl of 1 to 12 carbon atoms;

R<sup>4</sup> is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkoxy of 1 to 12 carbon atoms, amino, alkyl amino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, alkylthio of 1 to 12 5 carbon atoms, halogen, cyano, carboxy, alkoxycarbonyl of 2 to 12 carbon atoms, heterocyclyl, halogen, carbamoyl, optionally substituted aryl of 6, 10 or 14 carbon atoms, or -CF<sub>3</sub>; provided that when: a) R<sup>1</sup> is diethylamino, R<sup>3</sup> is chloro, R<sup>4</sup> is hydrogen, R<sup>2</sup> is not 4-trifluoromethylphenyl, 3,4-dichlorophenyl, 4-chlorophenyl, 3-chloro-4methoxyphenyl; b) R<sup>1</sup> is diethylamino, R<sup>3</sup> is bromo, R<sup>4</sup> is hydrogen, R<sup>2</sup> is not 10 4-trifluoromethylphenyl: c) R<sup>1</sup> is isopropylamino, R<sup>3</sup> is chloro, R<sup>4</sup> is hydrogen, R<sup>2</sup> is not 2-benzyloxyphenyl or 3,4,5-trimethoxyphenyl; d) R<sup>1</sup> is cyclopentylamino, R<sup>3</sup> is chloro, R<sup>4</sup> is hydrogen, R<sup>2</sup> is not 3,4,5-trimethoxyphenyl, 2-napthyl or 2-stilbene; e) R<sup>1</sup> is 2-aminobicyclo(2.2.1.)heptyl, R<sup>3</sup> is chloro, R<sup>4</sup> is hydrogen, R<sup>2</sup> is not 3,4,5-15 trimethoxyphenyl and f) R<sup>1</sup> is diethylamino, R<sup>3</sup> is chloro, R<sup>4</sup> is hydrogen, R<sup>2</sup> is not 4-trifluoromethylphenyl and g) R<sup>1</sup> is 1,1,1-trifluoroethoxy, R<sup>3</sup> is chloro, R<sup>4</sup> is hydrogen, R<sup>2</sup> is not 2-chloro-6-fluorophenyl h) R<sup>1</sup> is -SO<sub>2</sub>ethyl or -SO<sub>2</sub>cyclopentyl, R<sup>3</sup> is chloro, R<sup>4</sup> is hydrogen, R<sup>2</sup> is not 2-chloro-6fluorophenyl; i) R<sup>4</sup> is hydrogen, R<sup>2</sup> is 2-chloro-6-fluorophenyl, R<sup>1</sup> and R<sup>3</sup> are 20 not 1,2,4-triazole; j) R<sup>1</sup> is cyclohexyl, R<sup>4</sup> is hydrogen, R<sup>2</sup> is 2,4,6trifluorophenyl, and R<sup>3</sup> is not -OCH<sub>2</sub>O<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>; k) R<sup>1</sup> is 2-thienyl, R<sup>4</sup> is ethyl, R<sup>3</sup> is hydrogen and R<sup>2</sup> is not 2-methoxyphenyl, 4-methoxyphenyl, and 4-trifluorophenyl; I) R<sup>2</sup> is phenyl, R<sup>3</sup> is chloro, R<sup>4</sup> is hydrogen, R<sup>1</sup> is not (2E)-,7-dimethyl-2,6-octadienyl 25

Among the preferred groups of compounds of Formula (I) including pharmaceutically acceptable salts thereof useful for the methods of this invention are those in the subgroups below wherein the other variables of Formula (I) in the subgroups are as defined above wherein:

or a pharmaceutically acceptable salt thereof.

a) R<sup>1</sup> is selected from the group consisting of an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, optionally substituted bicycloalkyl of 5 to 10 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one –CH<sub>2</sub>-may also be replaced by –O-, -S-, or –NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of 5 to 10 carbon atoms in which one –CH<sub>2</sub>- may also be replaced by –O-, -S-, or –NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -SO<sub>2</sub>aryl of 6, 10 or 14 carbon atoms, -SO<sub>2</sub>alkyl of 1 to 12 carbon atoms, -O-aryl of 6, 10 or 14 carbon atoms, and the moiety –NR<sup>a</sup>R<sup>b</sup>;

15

25

30

5

10

- b)  $R^a$  and  $R^b$  each independently represent the moiety  $-C^*H(R^e)(R^f)$  where  $R^e$  and  $R^f$  independently represent an optionally halo-substituted alkyl group of 1 to 12 carbon atoms where  $C^*$  represents the (R) or (S) isomer;
- c) R<sup>2</sup> is optionally substituted aryl of 6, 10 or 14 carbon atoms, aryloxy, thienyl, benzyloxy, heterocyclyl or halogen;
  - d)  $R^3$  is halogen, alkyl of 1 to 12 carbon atoms, alkoxy of 1 to 12 carbon atoms, aryloxy, -NR $^c$ R $^d$ , benzyloxy, aralkyloxy, haloalkoxy of 1 to 12 carbon atoms,
  - alkylthio of 1 to 12 carbon atoms, hydroxy, cyano, amino, alkylamino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, or  $-N_3$ ;
  - e) R<sup>4</sup> is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkoxy of 1 to 12 carbon atoms, amino, alkyl amino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, -CF<sub>3</sub>;

10

15

20

Among the additionally preferred groups of compounds of this invention according to general Formula (I) including pharmaceutically acceptable salts thereof useful for the methods of this invention are those in the subgroups below, wherein the other variables of Formula (I) in the subgroups are as defined above wherein:

- a) R<sup>1</sup> is selected from the group consisting of an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkynyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, optionally substituted bicycloalkyl of 5 to 10 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one –CH<sub>2</sub>-may also be replaced by –O-, -S-, or –NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of 5 to 10 carbon atoms in which one –CH<sub>2</sub>- may also be replaced by –O-, -S-, or –NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -SO<sub>2</sub>aryl of 6, 10 or 14 carbon atoms, -SO<sub>2</sub>alkyl of 1 to 12 carbon atoms, -O-aryl of 6, 10 or 14 carbon atoms, and the moiety –NR<sup>a</sup>R<sup>b</sup> wherein R<sup>a</sup>R<sup>b</sup> are optionally taken together with the nitrogen to which each is attached;
- b) R<sup>2</sup> is optionally substituted aryl of 6, 10 or 14 carbon atoms or heterocyclyl;
- c) R³ is halogen, alkoxy of 1 to 12 carbon atoms, -NR°Rd , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, amino, alkylamino of 1 to 12 carbon atoms, or -N₃;
- d) R<sup>4</sup> is H, optionally substituted alkyl of 1 to 12 carbon atoms, amino, alkyl amino of 1 to 12 carbon atoms, dialkylamino of 1 to 12 carbon atoms, -CF<sub>3</sub>;

Among the more preferred groups of compounds of Formula (I) including pharmaceutically acceptable salts thereof useful for the methods of this invention are those in the subgroups below including the pharmaceutically acceptable salts thereof wherein the other variables of Formula (I) in the subgroups are as defined above wherein:

- a) R<sup>1</sup> is selected from the group consisting of an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one –CH<sub>2</sub>- may also be replaced by –O-, -S-, or –NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of 5 to 10 carbon atoms in which one –CH<sub>2</sub>- may also be replaced by –O-, -S-, or –NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -SO<sub>2</sub>aryl of 6, 10 or 14 carbon atoms, -SO<sub>2</sub>cycloalkyl of 5 to 10 carbon atoms, -SO<sub>2</sub>alkyl of 1 to 12 carbon atoms, and the moiety -NR<sup>a</sup>R<sup>b</sup> wherein R<sup>a</sup>R<sup>b</sup> are optionally taken together with the nitrogen to which each is attached:
- b) R<sup>2</sup> is optionally substituted aryl of 6, 10 or 14 carbon atoms;
- c)  $R^3$  is halogen, alkoxy of 1 to 12 carbon atoms,  $-NR^cR^d$ , haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, or  $-N_3$ ;
- d) R<sup>4</sup> is H;

25

30

5

10

15

20

Among the most preferred groups of compounds of Formula (I) including pharmaceutically acceptable salts thereof useful for the methods of this invention are those in the subgroups below including the pharmaceutically acceptable salts thereof wherein the other variables of Formula (I) in the subgroups are as defined above wherein:

a)R<sup>1</sup> is selected from the group consisting of an optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one –CH<sub>2</sub>- may also be replaced by –O-, -S-, or –NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of 5 to 10 carbon atoms in which one

5 -CH<sub>2</sub>- may also be replaced by –O-, -S-, or –NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -SO<sub>2</sub>aryl of 6, 10 or 14 carbon atoms, -SO<sub>2</sub>cycloalkyl of 3 to 8 carbon atoms, -SO<sub>2</sub>alkyl of 1 to 12 carbon atoms, and the moiety –NR<sup>a</sup>R<sup>b</sup> wherein R<sup>a</sup>R<sup>b</sup> are optionally taken together with the nitrogen to which each is attached; R<sup>2</sup> is optionally substituted phenyl; R<sup>3</sup> is halogen, alkoxy of 1 to 12 carbon atoms, -NR<sup>c</sup>R<sup>d</sup>, haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, or -N<sub>3</sub>; R<sup>4</sup> is H;

- b) R<sup>1</sup> is the moiety -NR<sup>a</sup>R<sup>b</sup> wherein R<sup>a</sup>R<sup>b</sup> are optionally taken together with the nitrogen to which each is attached; R<sup>2</sup> is optionally substituted phenyl; R<sup>3</sup> is halogen, alkoxy of 1 to 12 carbon atoms, -NR<sup>c</sup>R<sup>d</sup>, haloalkoxy of 1 to 12 carbon atoms, cyano, or -N<sub>3</sub>; R<sup>4</sup> is H;
- c) R<sup>1</sup> is the moiety -NR<sup>a</sup>R<sup>b</sup> wherein R<sup>a</sup>R<sup>b</sup> are optionally taken together with the nitrogen to which each is attached;

R<sup>2</sup> is optionally substituted phenyl;

R<sup>3</sup> is halogen, alkoxy, -NR<sup>c</sup>R<sup>d</sup>, haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, or -N<sub>3</sub>;

 $R^4$  is H;

R<sup>a</sup> is H, optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon

10

15

20

atoms, in which one -CH2- may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of 5 to 10 carbon atoms, in which one –CH<sub>2</sub>- may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, heterocyclyl, benzyl, optionally substituted benzyl: Rb is H. an optionally substituted alkyl of 1 to 12 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted aryl of 6, 10 or 14 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms in which one -CH<sub>2</sub>may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, optionally substituted cycloalkenyl of 5 to 10 carbon atoms in which one -CH<sub>2</sub>- may also be replaced by -O-, -S-, or -NR' where R' is H or an alkyl group of 1 to 12 carbon atoms, -S-aryl of 6, 10 or 14 carbon atoms, -S-alkyl of 1 to 12 carbon atoms, -S-alkenyl of 2 to 12 carbon atoms, -SO<sub>2</sub>aryl of 6, 10 or 14 carbon atoms, -SO<sub>2</sub>cycloalkyl of 3 to8 carbon atoms, -SO<sub>2</sub>alkyl of 1 to 12 carbon atoms, -O-aryl of 6, 10 or 14 carbon atoms; R<sup>a</sup>R<sup>b</sup> together with the nitrogen atom to which each is attached represent an optionally substituted saturated or unsaturated heterocyclyl ring from 3 to 12 ring atoms in which optionally, at least one -CH<sub>2</sub>- may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 2 to 12 carbon atoms, said saturated or unsaturated heterocyclyl ring may optionally be aryl or cycloalkyl fused;

10

15

20


25

 $R^c$  is H, amino, optionally substituted alkyl of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 8 carbon atoms, in which one  $-CH_2$ - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of 5 to 10 carbon atoms, in which one  $-CH_2$ - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted bicycloalkyl of 5 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, or heterocyclyl;

 $R^d$  is H, amino, optionally substituted alkyl of 1 to 12 carbon atoms, haloalkyl of 1 to 10 carbon atoms, optionally substituted alkenyl of 2 to 12 carbon atoms, optionally substituted alkadienyl of 4 to 12 carbon atoms, optionally substituted cycloalkyl of 3 to 10 carbon atoms, in which one  $-CH_2$ - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted cycloalkenyl of 5 to 10 carbon atoms, in which one  $-CH_2$ - may also be replaced by -O-, -S-, or -NR where R is H or an alkyl group of 1 to 12 carbon atoms optionally substituted bicycloalkyl of 5 to 10 carbon atoms, aryl of 6, 10 or 14 carbon atoms, benzyl , optionally substituted benzyl, or heterocyclyl;

R<sup>c</sup>R<sup>d</sup> together with the nitrogen atom to which each is attached represent an optionally substituted heterocyclyl ring from 3 to 8 ring atoms optionally substituted in which one –CH<sub>2</sub>- may also be replaced by –O-, -S-, or –NR' where R' is H or alkyl of 2 to 20 carbon atoms;

- d) R<sup>1</sup> is the moiety -NR<sup>a</sup>R<sup>b</sup> wherein R<sup>a</sup>R<sup>b</sup> are optionally taken together with the nitrogen to which each is attached;
- 30 R<sup>2</sup> is selected from



$$\begin{array}{c} & & & \\ & &$$

F 
$$OCH_2$$
  $OCH_2$   $OCH_2$   $OCH_2$   $OCH_2$ 

- R<sup>3</sup> is halogen, alkoxy, -NR<sup>c</sup>R<sup>d</sup>, haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, or -N<sub>3</sub>;
  - R<sup>4</sup> is H;
  - e)  $R^1$  is the moiety  $-NR^aR^b$  wherein  $R^aR^b$  are optionally taken together with the nitrogen to which each is attached and wherein  $R^1$  is selected from

 $R^2$  is optionally substituted phenyl;  $R^3 \ \text{is halogen, alkoxy of 1 to 12 carbon atoms, -NR}^c R^d \ , \ \text{haloalkoxy of 1 to 12 carbon atoms, cyano, or -N}_3;$ 

5

R<sup>4</sup> is H;

f)  $R^1$  is the moiety  $-NR^aR^b$  wherein  $R^aR^b$  are optionally taken together with the nitrogen to which each is attached and wherein  $R^1$  is selected from

R<sup>2</sup> is optionally substituted thienyl;

R³ is halogen, alkoxy of 1 to 12 carbon atoms, -NR°R¹, haloalkoxy of 1 to 12 carbon atoms, alkylthio of 1 to 12 carbon atoms, cyano, or -N₃;

## R4 is H;

5

10

15

20

Also, among the most particularly preferred compounds for the methods of this invention according to Formula (I) are the following compounds or a pharmaceutically acceptable salt thereof:
7-(1-azepanyl)-5-chloro-6-phenyl[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2,6-difluorophenyl)-7-(4-methyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(4-methoxyphenyl)-7-(1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2-chloro-6-fluorophenyl)-7-(4-methyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine;

7-(1-azepanyl)-5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2-chloro-6-fluorophenyl)-7-(2-methyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2-chloro-6-fluorophenyl)-7-(4-thiomorpholinyl)[1,2,4]triazolo[1,5-a]pyrimidine;

25 methyl [[5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl](methyl)amino]acetate;

5-chloro-6-(2-chloro-6-fluorophenyl)-N-(1,1,3,3-tetramethylbutyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

25

 $7\hbox{-}(1\hbox{-}azepanyl)\hbox{-}5\hbox{-}chloro\hbox{-}6\hbox{-}(4\hbox{-}methoxyphenyl)[1,2,4]triazolo[1,5\hbox{-}a]pyrimidine;$ 

7-(1-azepanyl)-6-(4-bromophenyl)-5-chloro[1,2,4]triazolo[1,5-a]pyrimidine;

5 5-chloro-7-(1-piperidinyl)-6-[2-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidine;

6-(4-tert-butylphenyl)-5-chloro-7-(4-methyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(4-methoxyphenyl)-7-(4-methyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(4-methoxyphenyl)-7-(3-methyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine;

6-(4-bromophenyl)-5-chloro-7-(3-methyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(3,4-difluorophenyl)-7-(4-methyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2,6-dichlorophenyl)-7-(2-methyl-1-pyrrolidinyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2-chlorophenyl)-7-(2-methyl-1-pyrrolidinyl)[1,2,4]triazolo[1,5-a]pyrimidine;

7-(1-azepanyl)-5-chloro-6-(3-chloro-4-methoxyphenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(3-chloro-4-methoxyphenyl)-7-(4-methyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(3-chloro-4-methoxyphenyl)-7-(2-methyl-1-

5 piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine;

6-(4-tert-butylphenyl)-5-chloro-7-(2-methyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-7-(2-methyl-1-piperidinyl)-6-[3-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidine;

Diethyl 2-[6-(2,6-difluorophenyl)-5-ethoxy[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]malonate;

15

20

7-(azepanyl)-5-chloro-6-{2-chloro-6-nitrophenyl}[1,2,4}triazolo[1,5-a]pyrimidine;

5-chloro-6-(2-chloro-6-fluorophenyl)-N-ethyl-N-(2-methyl-2-propenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-6-(2-chloro-6-fluorophenyl)-N-(2,2,2- trifluoroethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-6-(2-chloro-6-fluorophenyl)-N-[(2,2-dichlorocyclopropyl)methyl]-N-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

1-[5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]-3-piperidinol;

N-bicyclo[2.2.1]hept-2-yl-5-chloro-6-(3-chloro-4-methoxyphenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-6-(2,5-difluorophenyl)-N-dodecyl[1,2,4]triazolo[1,5-a]pyrimidin-7-

5 amine;

5-chloro-7-(4-methyl-1-piperidinyl)-6-(2,3,6- trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

N-[5-chloro-6-(2,3,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]-N- isopropylamine;

5-chloro-N-ethyl-N-(2-methyl-2-propenyl)-6-(2,3,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

N-allyl-5-chloro-6-(2-chloro-6-fluorophenyl)-N-(2-methyl-2-propenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-6-(3-chloro-4-methoxyphenyl)-N-cycloheptyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-6-(3-chloro-4-methoxyphenyl)-7-(3,3-dimethyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-N-(3-chloropropyl)-N-methyl-6-(2,3,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

7-(1-azocanyl)-5-chloro-6-(2,3,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

10

20

```
5-chloro-6-(2,6-difluorophenyl)-7-(3,6-dihydro-1(2H)-pyridinyl)[1,2,4]triazolo[1,5-a]pyrimidine;
```

7-(1-azocanyl)-5-chloro-6-(2,6-difluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-methoxy-6-(2-chloro-6-fluorophenyl)-7-(4-methyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine;

[5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]methanol;

1-[5-chloro-6-(2,6-difluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]-4-piperidinol;

5-chloro-7-(4-chloro-1-piperidinyl)-6-(2,6-difluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-7-(4-thiomorpholinyl)-6-(2,3,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2,6-difluorophenyl)-7-(2,4-dimethyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine;

7-(4-methyl-1-piperidinyl)-5-amino-6-(2-chloro-6fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2,6-difluorophenyl)-7-(2,5-dihydro-1H-pyrrol-1-yl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2-chloro-6-fluorophenyl)-7-(2,5-dimethyl-2,5-dihydro-1H-pyrrol-1-yl)[1,2,4]triazolo[1,5-a]pyrimidine;

```
5-chloro-6-(2-chloro-6-fluorophenyl)-7-(2-ethyl-1H-imidazol-1-yl)[1,2,4]triazolo[1,5-a]pyrimidine;
```

5 7-(4-bromo-1-piperidinyl)-5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2-methylphenyl)-7-(4-thiomorpholinyl)[1,2,4]triazolo[1,5-a]pyrimidine;

6-(2-bromophenyl)-N-(sec-butyl)-5-chloro[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-N-ethyl-6-(4-methoxyphenyl)-N-(2-methyl-2-propenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

15

5-chloro-6-(4-methoxyphenyl)-7-(4-thiomorpholinyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-7-(4-chloro-1-piperidinyl)-6-[2-

20 (trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2-chloro-6-fluorophenyl)-7-[4-(trifluoromethyl)-1-piperidinyl][1,2,4]triazolo[1,5-a]pyrimidine;

7-(4-bromo-1-piperidinyl)-5-chloro-6-(2,6-difluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

7-(4-bromo-1-piperidinyl)-5-chloro-6-(2-chlorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-N-ethyl-N-(2-methyl-2-propenyl)-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-N-isopropyl-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5- a]pyrimidin-7- amine;

5-chloro-7-(4-thiomorpholinyl)-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

7-(1-azepanyl)-5-chloro-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2-chloro-6-fluorophenyl)-7-[2-(1-pyrrolidinyl)-1-cyclopenten-1-yl][1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-7-(4-isopropyl-1-piperidinyl)-6-(4-methoxyphenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-7-(2,4-dimethyl-1-piperidinyl)-6-(4-methoxyphenyl)[1,2,4]triazolo[1,5-20 a]pyrimidine;

5-chloro-7-[ethyl(2-methyl-2-propenyl)amino]-6-{4-nitrophenyl}[1,2,4]triazolo[1,5-a]pyrimidine;

7-(1-azepanyl)-5-chloro-6-{4-nitrophenyl}[1,2,4]triazolo[1,5-a]pyrimidine;

N-bicyclo[2.2.1]hept-2-yl-5-chloro-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-6-(2,6-difluorophenyl)-N-(2,2,2-trifluoroethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-6-(2-chlorophenyl)-N-(2,2,2-trifluoroethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5 5-chloro-6-(2-chloro-6-fluorobenzyl)-7-tetrahydro-2-furanyl[1,2,4]triazolo[1,5-a]pyrimidine;

7-(allylsulfanyl)-5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

10.

15

5-chloro-N-ethyl-6-mesityl-N-(2-methyl-2-propenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-N-ethyl-6-(2-methoxyphenyl)-N-(2-methyl-2-propenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-6-(2-chloro-6-fluorophenyl)-N-hexyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine:

5-chloro-7-(4-methyl-1-piperidinyl)-6-[4-(methylsulfanyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-N-ethyl-N-(2-methyl-2-propenyl)-6-[4-(methylsulfanyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

25

N-(sec-butyl)-5-chloro-6-[4-(methylsulfanyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-6-[4-(methylsulfanyl)phenyl]-7-(4-thiomorpholinyl)[1,2,4]triazolo[1,5-a]pyrimidine;

15

```
5-chloro-6-[2,6-dichloro-4-(trifluoromethyl)phenyl]-7-(4-methyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine;
```

7-(1-azepanyl)-5-chloro-6-[2,6-dichloro-4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2-chloro-6-fluorophenyl)-7-[(2,2,2-trifluoroethyl)sulfanyl][1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2-chloro-6-fluorophenyl)-7-(4,4-dimethyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-[2,6-dichloro-4-(trifluoromethyl)phenyl]-N-ethyl-N-(2-methyl-2-propenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-6-[2,6-dichloro-4-(trifluoromethyl)phenyl]-7-(4-thiomorpholinyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(3,5-difluorophenyl)-7-(4-methyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2-chloro-6-fluorophenyl)-7-(isopropylsulfanyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2-chloro-6-fluorophenyl)-7-tetrahydro-2-furanyl[1,2,4]triazolo[1,5-a]pyrimidine;

 $\hbox{4-[5-chloro-7-(4-methyl-1-piperidinyl)]} \hbox{1,2,4]} triazolo \hbox{[1,5-a]} pyrimidin-6-yl] aniline;$ 

N-{4-[5-chloro-7-(4-methyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidin-6-yl]phenyl}acetamide;

25

[5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]methyl acetate;

5 5-chloro-6-(2-chloro-6-fluorophenyl)-7-(chloromethyl)[1,2,4]triazolo[1,5-a]pyrimidine;

diethyl 2-[6-(2-chloro-6-fluorophenyl)-7-(4-methyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidin-5-yl]malonate;

7-(1-azepanylmethyl)-5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

N-allyl-5-chloro-6-(2-chloro-6-fluorophenyl)-N-hexyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-7-(4-methyl-1-piperidinyl)-6-[4-(trifluoromethoxy)phenyl][1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-7-(4-methyl-1-piperidinyl)-6-(4-phenoxyphenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2-chloro-6-fluorophenyl)-N-(cyclopropylmethyl)-N-propyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-7-(2-methyl-1-piperidinyl)-6-(4-phenoxyphenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-{2-chloro-4-nitrophenyl}-7-(4-methyl-1-30 piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine;

```
5-chloro-6-(4-chloro-2,3,5,6-tetrafluorophenyl)-N-cyclopentyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;
```

4-[5-chloro-2-methyl-7-(4-methyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-N,N-dimethylaniline;

6-(2-chloro-6-fluorophenyl)-5-methyl-7-(4-methyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2-chloro-6-fluorophenyl)-7-[2-(1-pyrrolidinyl)-1-cyclohexen-1-yl][1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2-chloro-6-fluorophenyl)-7-(methoxymethyl)[1,2,4]triazolo[1,5-a]pyrimidine;

15

5-chloro-6-{2-chloro-4-nitrophenyl}-7-[ethyl(2-methyl-2-propenyl)amino][1,2,4]triazolo[1,5-a]pyrimidine;

5-bromo-6-(2-chloro-6-fluorophenyl)-7-(isopropylsulfanyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-N-cyclopentyl-6-(4-ethoxy-2,3,5,6-tetrafluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-N-methyl-N-(2-methyl-2-propenyl)-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

4-bromo-1-[5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]butyl acetate;

diethyl 2-allyl-2-{[5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]oxy}malonate;

6-(2-chloro-6-fluorophenyl)-N-ethyl-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin- 7-amine;

N-butyl-5-chloro-N-ethyl-6-(2,3,4,5,6-pentafluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

6-(2-chloro-6-fluorophenyl)-5-(difluoromethoxy)-7-(4-methyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2-chloro-6-fluorophenyl)-7-[(4-chlorophenyl)sulfanyl][1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2-chloro-6-fluorophenyl)-7-[(2-methoxyphenyl)sulfanyl][1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2-chloro-6-fluorophenyl)-N-(1,2,2trimethylpropyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-6-(2,3,4,5,6-pentafluorophenyl)-N-(1,2,2-trimethylpropyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-6-(2,4,6-trifluorophenyl)-N-(1,2,2-trimethylpropyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-6-(4-fluorophenyl)-N-(1,2,2- trimethylpropyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5,7-bis(4-methyl-1-piperidinyl)-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2-methylphenyl)-N-(1,2,2-trimethylpropyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-6-(2,4,5-trifluorophenyl)-N-(1,2,2-trimethylpropyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

6-(2-bromophenyl)-5-chloro-N-(1,2,2-trimethylpropyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-N-isobutyl-N-(2,2,2-trifluoroethyl)-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-N-isobutyl-6-(2-methylphenyl)-N-(2,2,2-trifluoroethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-6-(2-chloro-6-fluorophenyl)-N-(2,2,2-trifluoro-1-20 methylethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-6-(2,6-difluorophenyl)-N-(2,2,2-trifluoro-1-methylethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-N-(2,2,2-trifluoro-1-methylethyl)-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

N-allyl-5-chloro-N-isobutyl-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-N-(1,2-dimethylpropyl)-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-N-isopropyl-N-methyl-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-N-isopropyl-N-(2,2,2-trifluoroethyl)-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

7-butyl-5-chloro-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-N-(1-phenylethyl)-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-6-(2-chlorophenyl)-N-(2,2,2-trifluoro-1-methylethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-N-ethyl-N-isobutyl-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

20

5-chloro-6-(2-chloro-6-fluorophenyl)-7-hexyl[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2-methylphenyl)-N,N-bis(2,2,2-trifluoroethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

25

5-chloro-N-cyclopentyl-N-methyl-6-(2,3,4,5,6-pentafluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

7-butyl-5-chloro-6-(2,6-difluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

10

15

5-chloro-N-(1,2-dimethylpropyl)-N-methyl-6-(2,3,4,5,6-
pentafluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine

5-chloro-6-(2-chloro-6-fluorophenyl)-7-phenyl[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2-chloro-6-fluorophenyl)-7-(2-methylpropanyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2-chloro-6-fluorophenyl)-7-pentyl[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-N-(1,2-dimethylpropyl)-N-methyl-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-6-(2-chloro-6-fluorophenyl)-7-cyclohexyl[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2-bromo-5-chlorophenyl)-N-(2,2,2-trifluoro-1-methylethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-6-(2-chloro-6-fluorophenyl)-7-(3,3,3-trifluoropropyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2-chloro-6-fluorophenyl)-7-(3-methylphenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

[5-chloro-6-(2,4,6-trifluorophenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]-(1-p-tolyl-ethyl)-amine;

5-chloro-6-(2,4,6-trifluoro-phenyl)-7-cyclohexyl [1,2,4] triazolo [1,5-a] pyrimidine;

30

5-chloro-7-cyclohexyl-6-(2,3,4,5,6-pentafluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2-chloro-6-fluorophenyl)-7-(4,4-difluoro-1-

5 piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine;

7-(bicyclo[2.2.1]hept-2-ylamino)-5-chloro-6-{2-fluoro-4-nitrophenyl}[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-{2-fluoro-4-nitrophenyl}-7-(4-methyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-(methylsulfanyl)-6-(2-chloro-6-fluorophenyl)-7-cyclohexyl[1,2,4]triazolo[1,5-a]pyrimidine;

15

20

[5-chloro-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl] (2,2,2-trifluoro-1-phenylethyl)-amine;

5-chloro-N-[1-(trifluoromethyl)propyl]-6-(2,4,6trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-bromo-6-(2-chloro-6-fluorophenyl)-7-cyclohexyl[1,2,4]triazolo[1,5-a]pyrimidine;

6-(2-chloro-6-fluorophenyl)-7-cyclohexyl[1,2,4]triazolo[1,5-a]pyrimidin-5-amine;

[5-chloro-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]-(2-methyl-1-trifluoromethyl-propyl)amine;

20

5-chloro-7-(3-cyclohexen-1-yl)-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-7-(1-cyclohexen-1-yl)-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-N-[(1R)-2,2,2-trifluoro-1-methylethyl]-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-N-[(1R)-2,2,2-trifluoro-1-methylethyl]-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

6-(2,4-difluorophenyl)-5-chloro-N-(2,2,2-trifluoro-1-methylethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-(4-methyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-N-(2,2,2-trifluoro-1-methylethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-7-cyclohexyl-6-(2,6-difluoro-4-methoxyphenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-N-[(1S)-2,2,2-trifluoro-1-methylethyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

7-cyclohexyl-6-(2,6-difluoro-4-methoxyphenyl)-5-methoxy[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-7-(4-fluorocyclohexyl)-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2,6-dichloro-4-fluorophenyl)-7-(3,3,3-

5 trifluoropropyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

N-(sec-butyl)-5-chloro-6-(2,6-dichloro-4-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

4-{5-chloro-7-[(2,2,2-trifluoro-1-methylethyl)amino][1,2,4]triazolo[1,5-a]pyrimidin-6-yl}-3,6-difluorophenol;

5-chloro-7-(3-cyclohexen-1-yl)-6-(2,6-difluoro-4-methoxyphenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2,6-difluoro-4-methoxyphenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-N-cyclopentyl-6-(2,6-difluoro-4-methoxyphenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-(3,6-dihydro-1(2H)-pyridinyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-(4-thiomorpholinyl)[1,2,4]triazolo[1,5-a]pyrimidine;

7-(1-azepanyl)-5-chloro-6-(2,6-difluoro-4-methoxyphenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

```
5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-N-(1,2,2-trimethylpropyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;
```

5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-N-ethyl-N-(2-methyl-2-

5 propenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-(4-fluorocyclohexyl)[1,2,4]triazolo[1,5-a]pyrimidine;

6-(4-{5-chloro-7-[(2,2,2-trifluoro-1-methylethyl)amino][1,2,4]triazolo[1,5-a]pyrimidin-6-yl}-3,5-difluorophenoxy)hexanoic acid;

2,6-difluoro-4-(2-fluoroethoxy)phenyl]-N-(2,2,2-trifluoro-1-methylethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

15

20

5-chloro-N-isopropyl-6-{2-[(trifluoromethyl)sulfanyl]phenyl}[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-N-[4-(trifluoromethyl)phenyl]-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-N-(4,4,4-trifluoro-2-methylbutyl)-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-(3-methyl-3-butenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-isobutyl[1,2,4]triazolo[1,5-a]pyrimidine;

25

7-cyclopentyl-6-(2,6-difluoro-4-methoxyphenyl)-5-methoxy[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2-thienyl)-N-[(1R)-2,2,2-trifluoro-1-methylethyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

4-(5-chloro-7-(2,2,2-trifluoro-1-methyl-ethylamino)[1,2,4]triazolo[1,5-a]pyrimidin-6-yl]-3,5-difluoro-phenol;

10 {5-chloro-6-[2,6-difluoro-4-(2,2,2-trifluoro-ethoxy)-phenyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl}-(2,2,2-trifluoro-1-methyl-ethyl)amine;

5-chloro-6-{2,6-difluoro-4-(methoxyphenyl)-N-(2,2,2-trifluoro-1-methylethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

(5-chloro-6-{4-[2-(2-ethoxyethoxy]-ethoxy]-2,6-difluoro-phenyl}[1,2,4]triazolo[1,5-a]pyrimidin-7-yl-)-(2,2,2-trifluoro-1-methylethyl)amine;

20 (5-chloro-6-{2,6-difluoro-4-[2-(2-methoxy-ethoxy)ethoxy]-phenyl}- [1,2,4]triazolo[1,5-a]pyrimidin-7-yl-)-(2,2,2-trifluoro-1-methylethyl)amine;

5-chloro-6-[2,6-difluoro-4-(3-furan-3-ylmethoxy)phenyl[1,2,4]triazolo[1,5-a]pyrimidin-7-yl}-N-(2,2,2-trifluoro-1-methylethyl)amine;

5-chloro-6-(2,5-difluoro-4-methoxyphenyl)-N-(1,2,2-trimethylpropyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

7-cyclohexyl-6-[2,6-difluoro-4-(2-methoxyethoxy)phenyl]-5-30 methoxy[1,2,4]triazolo[1,5-a]pyrimidine;

20

```
5-chloro-6-(2-fluoro-4-methoxy-6-chlorophenyl)-N-(2,2,2-trifluoro-1-methylethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;
```

5-chloro-6-[2,6-difluoro-4-(2-fluoroethoxy)phenyl]-N-ethyl-N-(2-methyl-2-propenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

2-[2-(4-{5-chloro-7-[(2,2,2-trifluoro-1-methylethyl)amino][1,2,4]triazolo[1,5-a]pyrimidin-6-yl}-3,5-difluorophenoxy)ethoxy]ethanol;

5-chloro-6-(2,3-difluoro-4-methoxyphenyl)-N-(2,2,2-trifluoro-1-methylethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-6-{4-(2-fluoroethoxy)-2,6-difluorphenyl}-N-(2,2,2-trifluoro-1-methylethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-N-(4-chlorobenzyl)-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-6-(2-chloro-6-fluorophenyl)-7-[4-(2-pyridinyl)-1-piperazinyl][1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2-chloro-6-fluorophenyl)-N-(1-ethylpentyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-6-(2-chloro-6-fluorophenyl)-7-[4-(2-chlorophenyl)-1-piperazinyl][1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(2-chloro-6-fluorophenyl)-7-[4-(4-methoxyphenyl)-3-methyl-1-piperazinyl][1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-N-cyclopentyl-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-7-phenoxy-6-(4-methoxy-phenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5

5-chloro-N-cyclopentyl-6-(4-methylphenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5,7-diphenoxy-6-(4-methoxyphenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

10

5-chloro-N-cyclopentyl-6-(2-chlorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-N,N-diethyl-6-[4-methoxyphenyl][1,2,4]triazolo[1,5-a]pyrimidin-7amine;

5-chloro-N,N-diethyl-6-[2,4-dichlorophenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

N-bicyclo[2.2.1]hept-2-yl-5-chloro-6-(2,4-dichlorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-6-(2-chloro-6-fluorophenyl)-7-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)[1,2,4]triazolo[1,5-a]pyrimidine;

25

5-cyano-7-(4-methyl-1-piperidinyl)-6-(2-chloro-5-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-(methylsulfanyl)-7-(4-methyl-1-piperidinyl)-6-(2-chloro-6-30 fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

```
5-(methylsulfanyl)-7-(4-methyl-1-piperidinyl)-6-(2-chloro-5-(methylsulfanyl)phenyl)[1,2,4]triazolo[1,5-a]pyrimidine;
```

5-chloro-7-(1,4-dioxa-8-azaspiro[4,5]dec-8-yl)-6-(4methoxyphenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-N-ethyl-N-(2-methyl-2-propenyl)-6-(4-(methylsulfanyl)phenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

2-methyl-6,7-di-(4-methoxyphenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

2-methyl-6-phenyl-7-(4-chlorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

2-trifluoromethyl-6-phenyl-7-(4-methoxyphenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5,7-diphenoxy-6-(2-methylpropyl)[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(3,4-difluorophenyl)-N-(isopropyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

20

15

5-bromo-6-(4-bromophenyl)-7-dimethylamino[1,2,4]triazolo[1,5-a]pyrimidine;

5-bromo-6-(4-trifluoromethylphenyl)-7-dimethylamino[1,2,4]triazolo[1,5-a]pyrimidine;

25

5-chloro-6-(3,4-difluorophenyl)-7-dimethylamino[1,2,4]triazolo[1,5-a]pyrimidine;

5-chloro-6-(4-trifluoromethylphenyl)-N-(ethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-30 amine;

25

```
7-(1-azepanyl)-5-chloro-6-(4-tert-butylphenyl)[1,2,4]triazolo[1,5-a]pyrimidine; ethyl {[5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]amino}acetate;
```

diethyl 5-chloro-6-(2,6-difluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-malonate;

5-chloro-6-(2,5-difluorophenyl)-N-(3-methyl-2-butenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

[5-chloro-6-(2-chloro-6-fluorophenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]acetic acid methyl ester;

5-chloro-6-(2,6-difluorophenyl)-7-(2-ethyl-1H-imidazol-1-yl)[1,2,4]triazolo[1,5-a]pyrimidine;
5-chloro-N,N-diethyl-6-[4-(methylsulfanyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

ethyl [6-(2-chloro-6-fluorophenyl)-7-(4-methyl-1-piperidinyl)- [1,2,4]triazolo[1,5-a]pyrimidin-5-yl]acetate;

5-chloro-N-ethyl-N-(2-methyl-2-propenyl)-6-(4-phenoxyphenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

dimethyl 2-[5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]malonate;

diethyl 2-{[5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-30 yl]oxy}-2-isobutylmalonate;

```
2-[5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]-1,3-cyclohexanedione;
```

2-[5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]cyclohexanone;

```
5-chloro-7-(3-nitro-4-methylanilino)-6-(2, 4, 6-trifluorophenyl) [1,2,4]triazolo[1,5-a]pyrimidine;
```

7-cyclohexyl-6-[2,6-difluoro-4-(2-methoxyethoxy)phenyl]5-(2-methoxyethoxy)[1,2,4]triazolo[1,5-a]pyrimidine;

7-(3-bromophenyl)-2-ethyl-6-(4-methoxyphenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

15

7-(3-bromophenyl)-6-(3-chlorophenyl)-2-ethyl[1,2,4]triazolo[1,5-a]pyrimidine;

7-(4-bromophenyl)-2-ethyl-6-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidine;

20

5-chloro-6-(2-chloro-6-fluorophenyl)-N-(3,4,5-trimethoxybenzyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

7-(2-benzyl-4,5-dihydro-1H-imidazol-1-yl)-5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

N-4-[5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl-N,N-1-diethyl-1,4-pentanediamine;

5-chloro-N-(3-methyl-2-butenyl)-6-phenyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

15

5-dimethylamino-6-phenyl-N-cyclopentyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5 5-chloro-7-[(2-furylmethyl)sulfanyl]-6-(4-methoxyphenyl)[1,2,4]triazolo[1,5-a]pyrimidine;

6-[1,1'-biphenyl]-4-yl-5-chloro-N-cyclopentyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

6-[4-(benzyloxy)phenyl]-5-chloro-N-isopropyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-chloro-N-[(2,2-dichlorocyclopropyl)methyl]-6-(3,4,5-trimethoxyphenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

N-cyclopentyl-6-(2-fluorophenyl)-5-hydrazino[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

- 5-chloro-N-ethyl-6-(2-methylphenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;
  - 6-(4-tert-butylphenyl)-5-chloro-N-isopropyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;
- 5-chloro-6-[2,6-difluoro-4-[(3-methyl-2-butenyl)oxy]phenyl]-N-(2,2,2-trifluoro-1-methylethyl)-l[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;
  - 5-chloro-6-[2,6-difluoro-4-(1-propenyloxy)phenyl]-N-(2,2,2-trifluoro-1-methylethyl)-l[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

15

20

25

5-chloro-N-(3-tricyclo[2.2.1.0<sup>2,6</sup>]hept-1-yl)-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;

5-azido-7-cyclohexyl-6-(2-fluoro-6-chlorophenyl) [1,2,4]triazolo[1,5-a]pyrimidine;

5-azido-6-[2-chloro-6-fluorophenyl]-7-(4-methyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine;

2,5-dichloro-7-(4-methyl-1-piperidinyl)-6-[2-chloro-6-fluorophenyl][1,2,4]triazolo[1,5-a]pyrimidine.

It is understood that the definition of compounds of Formula (I), when R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>a</sup>, R<sup>b</sup>, R<sup>c</sup>, R<sup>d</sup>, or R<sup>c</sup> contain asymmetric carbons, encompass all possible stereoisomers and mixtures thereof which possess the activity discussed below. In particular, the definition encompasses racemic modifications and any optical isomers, (R) and (S), which possess the indicated activity. Optical isomers may be obtained in pure form by standard separation techniques or enantiomer specific synthesis. It is understood that this invention encompasses all crystalline forms of compounds of Formula (I). The pharmaceutically acceptable salts of the basic compounds of this invention are those derived from such organic and inorganic acids as: lactic, citric, acetic, tartaric, fumaric, succinic, maleic, malonic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, and similarly known acceptable acids. Where R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>a</sup>, R<sup>b</sup>, R<sup>c</sup>, R<sup>d</sup>, or R<sup>c</sup> contains a carboxyl group, salts of the compounds in this invention may be formed with bases such as alkali metals (Na, K, Li) or alkaline earth metals (Ca or Mg).

For the compounds defined above and referred to herein, unless otherwise noted, the following terms are defined.

The term halogen atom may denote a bromine, iodine, chlorine or fluorine atom, and is especially a bromine, chlorine or fluorine atom.

The terms alkyl, alkenyl, alkynyl, alkadienyl as used herein with respect to a radical or moiety refer to a straight or branched chain radical or moiety. As a rule, such radicals have up to 12, in particular up to 6 carbon atoms. Suitably an alkyl moiety has from 1 to 6 carbon atoms, preferably from 1 to 3 carbon atoms. A preferred alkyl moiety is an ethyl or especially a methyl group. Suitably an alkenyl moiety has from 2 to 12 carbon atoms. A preferred alkenyl moiety has from 2 to 6 carbon atoms. Most preferred is allyl or especially a 2methylallyl group. Any of the alkyl, alkenyl, alkynyl, alkadienyl groups as used herein with respect to the radical or moiety may optionally be substituted with one or more of substituents which include for example, halogen atoms, nitro, cyano, thiocyanato, cyanato, hydroxyl, alkyl, haloalkyl, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, formyl, aryl, alkoxycarbonyl, carboxyl, alkanoyl, alkylthio, alkylsulphinyl, alkylsulphonyl, carbamoyl, alkylamido, phenyl, phenoxy, benzyl, benzyloxy, heterocyclyl, especially furyl, and cycloalkyl, especially cyclopropyl, groups. Typically, 0-3 substituents may be present.

20

25

30

5

10

15

Cycloalkyl or cycloalkenyl as used herein with respect to a radical or moiety refer to a cycloalkyl or cycloalkenyl group having 3 to 8 carbon atoms preferably 3 to 6 carbon atoms or a cycloalkenyl group having 5 to 8 carbon atoms, preferably 5 to 7 carbon atoms, in particular cyclopentyl, cyclohexyl or cyclohexenyl being optionally substituted by one or more of substituents which include for example, halogen atoms, nitro, cyano, thiocyanato, cyanato, hydroxyl, alkyl, haloalkyl, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, formyl, alkoxycarbonyl, carboxyl, alkanoyl, alkylthio, alkylsulphinyl, alkylsulphonyl, carbamoyl, alkylamido, phenyl, phenoxy, benzyl, benzyloxy, heterocyclyl, especially furyl, and cycloalkyl, especially cyclopropyl, groups. Typically, 0-3 substituents may be present. Optionally, -CH<sub>2</sub>- group of the

cycloalkyl or cycloalkenyl radical or moiety may optionally be replaced with -O-, -S- or –NR' where R' is H or an alkyl group of 2 to 12 carbon atoms.

A bicycloalkyl group may contain from 5 to 10 carbon atoms.

5

Aryl as used herein with respect to the radical or moiety refers to an aryl group having 6, 10 or 14 carbon atoms, preferably 6 to 10 carbon atoms, in particular, phenyl, or naphthyl group being optionally substituted by one or more independently selected substituents which include, halogen atoms, nitro, cyano, alkenyl, thiocyanato, cyanato, hydroxyl, alkyl, haloalkyl, alkoxy, alkenyloxy, haloalkoxy, amino, alkylamino, dialkylamino, formyl, alkoxycarbonyl, carboxyl, alkanoyl, alkylthio, alkylsulphinyl, alkylsulphonyl, carbamoyl, alkylamido, phenyl, phenoxy, benzyl, benzyloxy, heterocyclyl, and cycloalkyl, groups. Typically, 0-5 substituents may be present.

15

10

Aralkyl as used herein means an aryl-alkyl group in which the aryl and alkyl group are previously defined. Exemplary aralkyl groups include benzyl and phenethyl.

20 Aralkyloxy as used herein refers to an aryl-alkyl-O- group in which the alkyl group and aryl group are previously described.

Phenyl as used herein refers to a 6-membered aromatic ring.

Heterocyclyl group may be a single ring, a bicyclic ring system or a system of annelated or spiro-fused rings as a saturated or unsaturated moiety or radical having 3 to 12 ring atoms with 5 to 8 ring atoms preferred with 5 or 6 ring atoms more preferred selected from carbon, oxygen, sulfur and nitrogen, one or more, typically one or two, of which being oxygen, nitrogen or sulfur, being optionally substituted by one or more of substituents which include for example, halogen atoms, preferably fluorine, nitro, cyano, thiocyanato,

cyanato, hydroxyl, alkyl of 1 to 12 carbon atoms, preferably 1 to 6 carbon atoms, haloalkyl, preferably haloalkyl of 1 to 6 carbon atoms, alkoxy, alkoxy of 1 to 12 carbon atoms, preferably alkoxy of 1 to 6 carbon atoms, haloalkoxy, amino, alkylamino, dialkylamino, formyl, alkoxycarbonyl, carboxyl, alkanoyl, alkylthio, alkylsulphinyl, alkylsulphonyl, carbamoyl, alkylamido, phenyl, phenoxy, benzyl, benzyloxy, heterocyclyl, especially furyl, and cycloalkyl, especially cyclopropyl, groups. Typically, 0-3 substituents may be present. Optionally substituted heterocyclyl groups include pyrrolodinyl, pyrrazolidinyl, piperidinyl, piperazinyl or morpholin-4-yl, pyridinyl, 2,3-dehydropiperid-3-yl, tetrahydropyranyl, tetrahydrofuranyl or tetrahydrothienyl, N-methyl-2,3-dehydropiperid-3-yl. pyrimidinyl, pyrrolidinyl, furyl, pyranyl, morpholinyl, tetrahydropyridine, thienyl, pyrrolidinyl, piperidyl, dihydropiperidyl, dihydropyridinyl, thiazanyl, morpholinyl, thiazinyl, azepanyl, azocanyl and dioxa-aza- spiro-decyl.

15

20

25

30

10

5

When any of the foregoing substituents are designated as being optionally substituted, the substituent groups which are optionally present may be any one or more of substituents which include for example, halogen atoms, nitro, cyano, thiocyanato, cyanato, hydroxyl, alkyl, haloalkyl, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, formyl, alkoxycarbonyl, carboxyl, alkanoyl, alkylthio, alkylsulphinyl, alkylsulphonyl, carbamoyl, alkylamido, phenyl, phenoxy, benzyl, benzyloxy, heterocyclyl, especially furyl, and cycloalkyl, especially cyclopropyl, groups. Typically, 0-3 substituents may be present. When any of the foregoing substituents represents or contains an alkyl substituent group, this may be linear or branched and may contain up to 12, preferably up to 6, and especially up to 4, carbon atoms. When any of the foregoing substituents represents or contains an aryl or cycloalkyl moiety, the aryl or cycloalkyl moiety may itself be substituted by one or more halogen atoms, nitro, cyano, alkyl, haloalkyl, alkoxy or haloalkoxy groups. In the case of cycloalkyl and heterocyclyl groups, optional substituents also include groups which together with two adjacent carbon atoms of the cycloalkyl or

20

25

heterocyclyl group form a saturated or unsaturated hydrocarbyl ring. In other words, a saturated or unsaturated hydrocarbyl ring may be optionally fused with the cycloalkyl or heterocyclyl group.

When any of the foregoing substituents represents or contains an aryl or cycloalkyl moiety, the aryl or cycloalkyl moiety may itself be substituted by one or more halogen atoms, nitro, cyano, alkyl, haloalkyl, alkoxy or haloalkoxy groups. In the case of cycloalkyl and heterocyclyl groups, optional substituents also include groups which together with two adjacent carbon atoms of the cycloalkyl or heterocyclyl group form a saturated or unsaturated hydrocarbyl ring. In other words, a saturated or unsaturated hydrocarbyl ring may be optionally fused with the cycloalkyl or heterocyclyl group.

Optionally substituted moieties may be unsubstituted or have from one up to the maximal possible number of substituents. Typically, 0 to 3 substituents are present.

The present invention accordingly provides a pharmaceutical composition which comprises a compound of this invention in combination or association with a pharmaceutically acceptable carrier. In particular, the present invention provides a pharmaceutical composition which comprises an effective amount of a compound of this invention and a pharmaceutically acceptable carrier. As used in accordance with this invention, the term providing an effective amount of a compound means either directly administering such compound, or administering a prodrug derivative, or analog which will form an effective amount of the compound within the body.

#### DESCRIPTION OF THE INVENTION

Compounds of this invention are prepared according to the procedures described in U.S. Patent Nos. 5,593,996; 5,756,509;5,948,783; 5,981,534;

25

5,612,345; 5,994,360; 6,020,338; 5,985,883; 5,854,252; 5,808,066; 5,817,663; 5,955,252; 5,965,561; 5,986,135; and 5,750,766 which are hereby incorporated herein by reference.

Standard pharmacological test procedures that showed that the compounds of this invention possess significant activity as promoters of microtubule polymerization and are antineoplastic agents. Based on the activity shown in the standard pharmacological test procedures, the compounds of this invention are therefore useful as anticancer agents. Associated cancers are selected from the group consisting of breast, colon, lung, prostate, melanoma, epidermal, leukemia, kidney, bladder, mouth, larynx, esophagus, stomach, ovary, pancreas, liver, skin and brain. In particular the compounds of this invention possess an effect similar to Paclitaxel. The test procedures used and results obtained are shown below.

## CYTOTOXICITY STANDARD PHARMACOLOGICAL TEST PROCEDURE USING MTS AS DETECTION REAGENT

This standard pharmacological test procedure identifies representative examples of substituted triazolopyrimidine compounds of the invention, which further includes compounds of Formula (I), which kill various human cancer cell lines. The test is based on the conversion by viable cells, but not by dead cells, of the tetrazolium salt, MTS, into a water-soluble colored formazan which is detected by spectrophotometry. The test procedure was used to identify the most potent compounds within a series of related structures which were known or suspected to have a microtubule mechanism of action. The most potent compounds were then taken forward into other test procedures which specifically analyzed effects on microtubules.

15

20

25

#### Part 1. Cytotoxicity with HeLa Cells

In the first cytotoxicity test, representative compounds of the invention were tested with the HeLa human cervical carcinoma cell line at a single concentration. HeLa cells (ATCC CCL2.2) were routinely maintained by twice-weekly subculture in fresh medium. Medium was RPMI-1640 with L-glutamine, supplemented with 10% heat-inactivated fetal calf serum, 100 units/ml penicillin, and 100 µg/ml streptomycin.

For assay, HeLa cells were harvested by trypsinization, washed, counted and distributed to wells of 96-well flat-bottom microtiter plates at 1000 cells per well in 100  $\mu$ l of medium. The plates were incubated at 37° in humidified 5% CO<sub>2</sub> in air for about 24 hr.

On day 2, compounds for test were diluted and added to wells. Compounds were dissolved in dimethyl sulfoxide (DMSO) at 10 mg/ml. These solutions were diluted into medium to give solutions of 20 µg/ml, and then 100 µl was added in duplicate to wells already containing cells, to give final drug concentrations of 10 µg/ml and a final DMSO concentration of 0.1%. Each plate also contained the following controls: cells with no drug (uninhibited cell growth = maximal MTS response = control response); cells plus 100 nM paclitaxel (all cells killed = minimal MTS response); and medium only (MTS reagent control). The plates were returned to the incubator for three days.

After three days of culture with test compounds (day 5 overall), the MTS assay was done on all wells of the plates. Twenty µl of the combined MTS/PMS reagent (Promega "CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay," catalog no. G5421; see Technical Bulletin No. 169, Revised 9/96) were added to each well with a repeating pipettor, and the plates were returned to the 37° incubator for 2 hr before recording the absorbance of each well at 490 nm using an ELISA plate reader.

The absorbance values of the duplicate sample wells were averaged and expressed as a percentage of the average value of the control wells. Percentages less than 100 indicated that the test compounds had exerted a cytotoxic effect on the cells. The results of this pharmacological test procedure are displayed in Table 1.

Table 1

Evaluation of Representative Compounds of the Invention in the MTS Cytotoxicity Standard Pharmacological Test Procedure with HeLa Cells

Ex No.	Percent of Control
	at 10 ug/ml
1	-1.6
2	10.4
4	2.9
5	-0.8
6	-0.4
7	0.6
8	2
9	8.1
12	0.3
19	-1.3
24	3.7
27	2.2
28	3.4
30	-0.4
32	20.3
33	-1.3
35	17.6
37	-1.6
38	0.2
39	10.6
41	7.1
42	-0.1

Table 1 (cont)				
Ex No.	Percent of Control at			
	10 ug/ml			
43	5.8			
47	0			
48	13.9			
49	12			
54	-0.1			
59	0.9			
60	4.9			
61	-1.2			
62	-0.7			
63	10.6			
64	-2			
65	-0.6			
66	-0.7			
70	1.4			
72	-1.8			
73	15.6			
79	7.1			
82	-1.5			
87	-0.2			
99	1.8			
102	1.1			
103	-0.7			
105	0			
113	-0.3			
116	-1.3			
117	-0.1			
121	-0.8			

Table 1 (cont)					
Ex No. Percent of Control					
	at 10 ug/ml				
122	2.1				
123	-2.2				
124	-1.6				
127	-0.9				
128	-0.3				
130	5.4				
132	3.4				
133	10.7				
135	-1.1				
140	-0.9				
141	10.8				
143	92.8				
144	2.3				
145	16.2				
146	16.1				
149	7.8				
150	3.4				
151	9.6				
157	-2.7				
158	-0.4				
159	-1				
160	1.1				
163	27.2				
167	-2.5				
168	8.7				
169	23.8				
170	22.6				

Table 1 (cont)				
Ex No. Percent of Contro				
	at 10 ug/ml			
172	-0.9			
173	-0.6			
174	0.6			
175	1.9			
176	-0.6			
177	8.5			
180	-0.3			
181	-1.5			
182	-1.7			
183	-0.1			
184	1.3			
185	1.5			
186	1			
187	-1.4			
188	8.8			
189	2.2			
213	10.2			
216	5.8			
217	-0.5			
225	-1			

### Part 2. Cytotoxicity with COLO 205 Cells

In the second cytotoxicity standard pharmacological test procedure, representative compounds of the invention were tested with the COLO 205 human colon adenocarcinoma cell line at six concentrations, in order to determine IC<sub>50</sub> values. COLO 205 cells (ATCC CCL 222) were routinely maintained by thrice-weekly subculture in fresh medium. Medium was RPMI-

10

15

20

25

30

1640 with L-glutamine, supplemented with 10% heat-inactivated fetal calf serum, 20 mM HEPES, 100 units/ml penicillin, and 100 μg/ml streptomycin.

For the test procedure, COLO 205 cells were harvested by trypsinization, washed, counted and distributed to wells of 96-well flat-bottom microtiter plates at 1000 cells per well in 100 µl of medium. In addition, one row of wells on an additional plate received cells as above ("time 0" plate). All plates were incubated at 37° in humidified 5% CO<sub>2</sub> in air for about 24 hr.

On day 2, compounds for test were diluted and added to wells. Compounds were dissolved in DMSO at 10 mg/ml. For each compound, six serial 3-fold dilutions were prepared in medium. The highest drug concentration with cells was 5 µg/ml and the highest DMSO concentration was 0.05%. Drugs were added in duplicate to wells in 100 µl volume. Each plate also contained the following controls: cells with no drug (uninhibited cell growth = maximal MTS response); cells plus 100 nM paclitaxel (all cells killed = minimal MTS response); and medium only (MTS reagent control). The plates were returned to the incubator for three days.

At the time of drug addition to the experimental plates, the MTS assay was run on the "time 0" plate. This produced the "time 0 MTS value" which was related to the number of viable cells per well at the time of drug addition. The MTS values of the wells of the experimental plates were lower than, higher than, or the same as the time 0 value, depending on whether a drug killed the cells, did not inhibit cell growth, or was cytostatic, respectively.

After three days of culture with test compounds (day 5 overall), the MTS assay was done on all wells of the experimental plates. The results for each plate were calculated separately, using its own controls. The absorbance values of the duplicate sample wells were averaged and divided by the average of the "time 0" values. The average of the control wells without drug, divided by the average "time 0" value, gave the maximal relative increase in MTS color yield due to cell growth during the final three days of culture. The average of the control wells with paclitaxel, divided by the "time 0"

10

value, gave the minimal relative color yield for cells that were completely killed. The six values for each compound were plotted against concentration, and the concentration that produced a relative color yield half way between the maximum and minimum was taken as the  $IC_{50}$  value. The most potent compounds had the lowest  $IC_{50}$  values. Test results of representative compounds of the invention are displayed in Table 2.

In addition, some compounds of the invention were tested in duplicate at 25 and 50  $\mu$ g/ml with COLO 205 cells in the MTS cytotoxicity pharmacological test procedure. Results were expressed as a percent of the average value of the control wells. Percentages less than 100 indicated that the test compounds had exerted a cytotoxic effect on the cells. These test results are also displayed in Table 2.

Table 2

Evaluation of Representative Compounds of the Invention in the MTS

Cytotoxicity Standard Pharmacological Test Procedure with COLO 205

Cells

(μg/ml)     25 μg/ml     50 μg/ml       1     0.84     2     0.092     3       3     0.82     4     0.082     5       5     0.057     6     0.16     7     0.12     8       8     3.3     9     0.86     9     0.86     9     0.35     11     2.5     12     0.32     2     13     4.3     14     0.22     15     1.2     16     4.8     17     0.91     18     0.33     19     0.25     20     1     2.8		1050		0/ 60 1:-1 14	
25 μg/ml 50 μg/ml  1 0.84 2 0.092 3 0.82 4 0.082 5 0.057 6 0.16 7 0.12 8 3.3 9 0.86 10 0.35 11 2.5 12 0.32 2 13 4.3 14 0.22 15 1.2 16 4.8 17 0.91 18 0.33 19 0.25 20 1 21 2.8	Ex No.	IC50	n	% of Control At	
1       0.84         2       0.092         3       0.82         4       0.082         5       0.057         6       0.16         7       0.12         8       3.3         9       0.86         10       0.35         11       2.5         12       0.32       2         13       4.3         14       0.22         15       1.2         16       4.8         17       0.91         18       0.33         19       0.25         20       1         21       2.8		(μg/ml)			
2       0.092         3       0.82         4       0.082         5       0.057         6       0.16         7       0.12         8       3.3         9       0.86         10       0.35         11       2.5         12       0.32       2         13       4.3         14       0.22         15       1.2         16       4.8         17       0.91         18       0.33         19       0.25         20       1         21       2.8				25 μg/ml 50 μg/ml	
3       0.82         4       0.082         5       0.057         6       0.16         7       0.12         8       3.3         9       0.86         10       0.35         11       2.5         12       0.32       2         13       4.3         14       0.22         15       1.2         16       4.8         17       0.91         18       0.33         19       0.25         20       1         21       2.8	1	0.84			
4       0.082         5       0.057         6       0.16         7       0.12         8       3.3         9       0.86         10       0.35         11       2.5         12       0.32       2         13       4.3         14       0.22         15       1.2         16       4.8         17       0.91         18       0.33         19       0.25         20       1         21       2.8	2	0.092			
5       0.057         6       0.16         7       0.12         8       3.3         9       0.86         10       0.35         11       2.5         12       0.32       2         13       4.3         14       0.22         15       1.2         16       4.8         17       0.91         18       0.33         19       0.25         20       1         21       2.8	3	0.82			
6       0.16         7       0.12         8       3.3         9       0.86         10       0.35         11       2.5         12       0.32       2         13       4.3         14       0.22         15       1.2         16       4.8         17       0.91         18       0.33         19       0.25         20       1         21       2.8	4	0.082			
7       0.12         8       3.3         9       0.86         10       0.35         11       2.5         12       0.32       2         13       4.3         14       0.22         15       1.2         16       4.8         17       0.91         18       0.33         19       0.25         20       1         21       2.8	5	0.057			
8       3.3         9       0.86         10       0.35         11       2.5         12       0.32       2         13       4.3         14       0.22         15       1.2         16       4.8         17       0.91         18       0.33         19       0.25         20       1         21       2.8	6	0.16			
9       0.86         10       0.35         11       2.5         12       0.32       2         13       4.3         14       0.22         15       1.2         16       4.8         17       0.91         18       0.33         19       0.25         20       1         21       2.8	7	0.12			
10     0.35       11     2.5       12     0.32     2       13     4.3       14     0.22       15     1.2       16     4.8       17     0.91       18     0.33       19     0.25       20     1       21     2.8	8	3.3			
11       2.5         12       0.32       2         13       4.3         14       0.22         15       1.2         16       4.8         17       0.91         18       0.33         19       0.25         20       1         21       2.8	9	0.86			
12     0.32     2       13     4.3       14     0.22       15     1.2       16     4.8       17     0.91       18     0.33       19     0.25       20     1       21     2.8	10	0.35			
13       4.3         14       0.22         15       1.2         16       4.8         17       0.91         18       0.33         19       0.25         20       1         21       2.8	11	2.5			
14     0.22       15     1.2       16     4.8       17     0.91       18     0.33       19     0.25       20     1       21     2.8	12	0.32	2		
15     1.2       16     4.8       17     0.91       18     0.33       19     0.25       20     1       21     2.8	13	4.3			
16     4.8       17     0.91       18     0.33       19     0.25       20     1       21     2.8	14	0.22			
17     0.91       18     0.33       19     0.25       20     1       21     2.8	15	1.2			
18     0.33       19     0.25       20     1       21     2.8	16	4.8			
19 0.25 20 1 21 2.8	17	0.91			
20     1       21     2.8	18	0.33			
21 2.8	19	0.25			
	20	1			
22 46	21	2.8			
1.0	22	4.6			

Table 2 (cont)						
Ex No.	IC50	n	% of Control At			ol At
	(μg/ml)					
			25	μg/ml	50	μg/ml
23	3.7					
24	>5					
25	>5 a					
26	0.33					
27	0.033					
28	0.08					
29	0.29					
30	0.31	2				
31	2.8					
32	>5					
33	0.062					
34	0.44					
35	0.026	3				
36	0.1					
37	>5					
38	2.5					
39	2.2					
40	0.31					
41	0.062					
42	0.33					
43	0.084					
44	0.64					
45	4.8		1			
46	0.31					
47	0.11					
48	0.13					

Table 2 (cont)					
Ex No.	IC50	n	% of Control At		
	(μg/ml)				
			25 μg/ml 50 μg/m		
49	0.15				
50	2.1				
51	0.86				
52	0.7				
53	1.3				
54	0.094				
55	0.59				
56	0.86				
57	0.64				
58	1				
59	0.18				
60	0.19				
61	0.095	:			
62	0.13				
63	0.16				
64	0.68	2			
65	0.18				
66	0.11				
67	0.34				
68	1.7	2			
69	0.36				
70	0.22				
71	0.87	2			
72	0.22				
73	0.13				
74	0.31				

Table 2 (cont)					
Ex No.	IC50	n	% of Control At		
	(μg/ml)				
			25 μg/ml 50 μg/ml		
75	4.3				
76	0.37	2			
77	0.66	2			
78	2.4				
79	0.27				
80	2.6	2			
81	2.5	2			
82	0.038				
83	3	2			
84	2.8				
85	2.8	2			
86	0.26	2			
87	0.24				
88	2.8	2			
89	2.9	2			
90	1				
91	0.39	2			
92	1.8				
93	2.7	2			
94	3.5	2			
95	3.8				
96	0.79	2			
97	>5 a				
98	2	2			
99	0.064				
100	>5 a				

Table 2 (cont)						
Ex No.	IC50	n	% of Control At			ol At
	(μg/ml)					
			25	μg/ml	50	μg/ml
101	4.4					
102	2.3					
103	0.27					
104	0.25	2				
105	0.12	2				
106	>5 a					
107	0.11	2				:
108	0.63	2				
109	3.5					
110	0.32	2				
111	0.39	2				
112	0.34					
113	0.91					
114	3.7					
115	>5 a					
116	>5					
117	0.26					
118	1.2	2				
119	0.75	2				
120	1.4	2				
121	2.7					
122	0.73					
123	>5					

Table 2 (cont)					
Ex No.	IC50	n	% of Control At		
	(μg/ml)				
			25	50	
			μg/ml	μg/ml	
124	0.12		M3	p-9/····	
		0			
125	4.7	2			
126	0.14				
127	0.056				
128	2.6				
129	0.31	2			
130	0.91				
131	0.1	2			
132	0.084				
133	0.092	2			
134	0.33	2			
135	0.16				
136	0.55	2			
137	1.2				
138	0.34	2			
139	0.96				
140	0.075				
141	0.28				
142	0.29	2			
143	0.097				
144	0.084				
145	2.5				
146	0.099				
147	1.2	2			
148	0.36				

Table 2 (cont)					
Ex No.	IC50	n	% of Control At		
	(μg/ml)				
			25 μg/ml 50 μg/m		
149	0.056				
150	0.28				
151	0.099				
152	1				
153	0.42				
154	1.2				
155	1.1				
156	0.11				
157	>5				
158	0.19				
159	0.38				
160	0.27				
161	2.6				
162	0.78				
163	0.27				
164	0.17				
165	0.96				
166	0.32				
167	0.1				
168	0.11				
169	0.31	4			
170	0.074	11			
171	0.29				
172	0.3				
173	0.3				
174	0.13				

	Table 2 (cont)					
Ex No.	IC50	n	% of Control At			
	(μg/ml)					
			25 μg/ml	50 μg/ml		
175	0.038	3				
176	0.1					
177	0.13					
178	0.099	3				
179	0.35					
180	0.81					
181	0.043					
182	1.3					
183	0.078					
184	0.25					
185	0.04					
186	0.034					
187	0.035					
188	0.012	2				
189	0.055					
190	0.33					
191	0.032					
192	>5 a					
193	0.95					
194	0.58					
195	0.1					
196	0.15					
197	0.3					
198	0.091	3				
199	0.38					

Table 2 (cont)							
Ex No.	IC50	n	% of Control At			ol At	
	(μg/ml)						
			25	μg/ml	50	μg/ml	
200	0.27						
201	0.39					· <del>-</del>	
202	0.25						
203	0.17						
204	0.12						
205	0.036						
206	0.12						
207	0.035						
208	0.014	2					
209	0.11						
210	0.31			<del></del>			
211	0.049	3					
212	0.88						
213	0.47						
214	0.79			· · · · · · · · · · · · · · · · · · ·			
215	3.5			,			
216	0.63						
217	0.2						
218	>5 a						
219	0.89						
220	4.9						
221	2.8						
222	5	2					
223	2.1						
224	0.3						

Table 2 (cont)						
Ex No.	IC50	n	% of Control At			
	(μg/ml)					
			25 μg/ml	50 μg/ml		
225	0.086					
226	0.095					
227	4.3					
228	>5 a					
229	0.95	2				
230	2.5					
231			44.3	6.6		
232			67.5	15.0		
233			27.3			
234			5.6			
235			80.6	14.7		
236			28.4	10.9		
237			24.1	-3.5		
238			100.4	41.5		
239			58.8	25.5		
240			-0.9	-4.0		
241			2.3	2.4		
242			13.1	-4.8		
243			12.7	-3.0		
244			9.2	21.0		
245			100.3	72.5		
246			4.0	-4.8		
247			63.6	46.4		
248			15.5	-3.9		
249			47.4	20.3		

Table 2 (cont)							
Ex No.	IC50	n	% of Control At				
	(μg/ml)						
			25 μg/ml	50 μg/ml			
250			16.4	4.6			
251			103.9	28.1			
252			94.8	69.6			
253			120.0	74.1			
254			39.6	15.6			
255			58.3	86.1			
256			20.2	14.8			
257			27.3	-3.5			
258			74.6	44.1			
259			32.6	0.7			
260			87.8	53.5			
261			7.4	-3.9			
262			23.7	-5.1			
263			-1.5	2.0			
264			34.5	-4.2			
265			8.1	-1.6			
266			84.9	72.4			
267			17.8	32.1			
268			-0.8	4.2			
269			3.5	11.9			
270	0.095						
271	0.32						
272	0.91						
273	1						
274	1.9						

15

Table 2 (cont)						
Ex No.	IC50	IC50 n % of Control At				
	(μg/ml)					
			25 μg/ml 50 μg/ml			
275	0.13					

#### Notes to Table 2:

- 1. n = number of independent assays (n = 1 unless stated otherwise)
  - 2. a means that at 5  $\mu g/\text{ml}$  the inhibition was between 30 and 50%

### Part 3. Cytotoxicity with H157, U87MG, PC-3 MM2, and DLD1 Cells

The cytotoxicity standard pharmacological test procedure with MTS detection was applied to representative compounds of the invention with four additional human cancer cell lines in order to characterize the range of tumor types against which the compounds were active. The cell lines used were H157 human non-small cell lung carcinoma, U87MG human glioblastoma, PC-3 MM2 human prostate carcinoma, and DLD1 human colon adenocarcinoma. The procedure of the test and the method of data calculation were the same as described above in Part 2 with COLO 205 cells. The results are displayed in Table 3.

Table 3

Evaluation of Representative Compounds of the Invention and Standard

Cytotoxic Agents in the MTS Cytotoxicity Standard Pharmacological Test

Procedure with Four Human Cancer Cell Lines

Example	IC <sub>50</sub> (nM)						
	H157	U87MG	PC-3 MM2	DLD1			
35	31	390	220	105			
169		>1000	>1000				
170	310	200	140	560			
175		180	240	215			
178		480	550				
186	38						
187	86						
188	16	48	73	48			
198		640	580				
205	83						
208	10	120	140	69			
211		370	400				
Camptothecin	10						
Colchicine	13	6.5	10	25			
Doxorubicin	17			170			
Mitoxantrone	13						
Nocodazole	33	34	43	40			
Paclitaxel			0.17	1.4			
Vincristine	0.28		0.30	3.0			

10

15

20

## Part 4. Cytotoxicity with KB Cells and Drug-Resistant Lines Derived from KB

The cytotoxicity standard pharmacological test procedure with MTS detection was applied to representative compounds of the invention with the KB human epidermoid carcinoma cell line and two multidrug resistant lines derived from it. These derived lines were colchicine-resistant KB 8.5, which expresses a moderate level of the multidrug transporter P-glycoprotein, and vinblastine-resistant KB VI, which expresses a high level of P-glycoprotein.

The purpose of these experiments was to determine if the compounds were able to overcome drug resistance mediated by P-glycoprotein. If the  $IC_{50}$ 's of the compounds are essentially the same on all three lines, then the compounds are not substrates of P-glycoprotein. If on the other hand, the compounds have much higher  $IC_{50}$ 's on KB 8.5 and KB VI compared to KB (as do paclitaxel, vincristine, and many other standard anti-cancer drugs) then they would be substrates of P-glycoprotein.

The procedure of the cytotoxicity test and the method of data calculation were the same as described above in Part 2 with COLO 205 cells. The results are displayed in Table 4. The results show that the compounds of this invention have essentially the same IC<sub>50</sub>'s on all three cell lines, indicating that they would not be subject to multidrug resistance mediated by P-glycoprotein.

10

15

Table 4
Evaluation of Representative Compounds of the Invention and Standard
Cytotoxic Agents in the MTS Cytotoxicity Standard Pharmacological Test
Procedure with Human Cancer Cell Lines that Overexpress the
P-glycoprotein Transporter

Example		IC <sub>50</sub> (nM)	IC <sub>50</sub> (nM)		Relative Resistance		
	КВ	KB 8.5	KB VI	КВ	KB 8.5	KB VI	
35	19	31	16	1	1.6	0.8	
186	30	48	33	1	1.6	1.1	
187	45	76	56	1	1.7	1.2	
188	10	18	11	1	1.8	1.1	
Taxol	<0.03	19	3,325	1	>630	>111,000	
Vincristine	<0.06	29	3,150	1	>480	>52,500	
Colchicine	7.2	51	1,330	1	7.1	185	
Nocodazole	21	24	33	1	1.1	1.6	
Doxorubicin	34	101	4,400	1	3.0	130	

## Part 5. Cytotoxicity with S1 Cells and a Drug-Resistant Line Derived from S1

The cytotoxicity standard pharmacological test procedure with MTS detection was applied to representative compounds of the invention with the S1 human colon carcinoma cell line and a multidrug resistant line derived from it. The derived line was mitoxantrone-resistant S1-M1, which expresses the multidrug transporter MXR. The purpose of these experiments was to determine representative compounds of the invention able to overcome drug resistance mediated by MXR. If the IC<sub>50</sub>'s of the compounds are essentially the same on both lines, then the compounds are not substrates of MXR. If on the other hand, the compounds have much higher IC<sub>50</sub>'s on S1-M1 compared

to S1 (as do many standard anti-cancer drugs) then they would be substrates of MXR.

The procedure of the cytotoxicity test and the method of data calculation were the same as described above in Part 2 with COLO 205 cells. The results are displayed in Table 5. The results show that the compounds of this invention have essentially the same IC<sub>50</sub>'s on both cell lines, indicating that they would not be subject to multidrug resistance mediated by MXR.

10

5

Table 5

Evaluation of Representative Compounds of the Invention and Standard Cytotoxic Agents in the MTS Cytotoxicity Pharmacological Test Procedure with a Human Cancer Cell Line that Overexpresses the MXR Transporter Protein

15

Example	IC <sub>50</sub>	(nM)	Relative Resista	
	S1	S1-M1	S1	S1-M1
35	73	94	1	1.3
186	99	102	1	1.0
187	99	124	1	1.3
188	33	74	1	2.2
Colchicine	11	47	1	4.3
Nocodazole	43	146	1	3.4
Doxorubicin	19	10,700	1	565
Mitoxantrone	<4	>10,000	1	>2,500
Camptothecin	6.8	. 21	1	3.1

10

15

20

25

30

# INHIBITION OF CELLULAR PROLIERATION STANDARD PHARMACOLOGICAL TEST PROCEDURE USING SULFORHODAMINE B AS DETECTION REAGENT

This standard pharmacological test procedure measures the ability of compounds to inhibit cellular proliferation. Sulforhodamine B staining was used to estimate total cellular protein in each culture after exposure to compounds. A decrease in staining compared to untreated control cultures indicated an inhibition of proliferation.

Two cell lines were used in these experiments: Reh human acute lymphocytic leukemia, and CCRF-CEM human acute lymphoblastic leukemia, both obtained from ATCC. Two types of experiments were done on each of the two cell lines. In the first, cells were cultured with Example 170 at several concentrations for either 24 or 72 hr, and the effect on cellular proliferation was determined. In the second, cells were cultured with Example 170 at several concentrations for 24 hr, the compound was removed and replaced with fresh medium without compound, culture was continued for another 48 hr, and the effect on cellular proliferation was determined. This second experiment determined the ability of cells to recover from the damage inflicted by compound during the first 24 hr of culture. At the end of the incubation periods, cells were fixed with trichloroacetic acid and stained with sulforhodamine B using the in vitro Toxicology Assay Kit (Sigma). Actinomycin D was used as a positive control in all experiments. Bound dye was measured spectrophotometrically at 565 nm with a reference wavelength of 690 nm. Cultures were done in 96-well assay plates with five replicates of each concentration. The absorbance values of the replicates were averaged and expressed as a percent of the vehicle control. Each experiment was repeated once, and the percent of control for a given concentration in each experiment were averaged to calculate the results displayed in Table 6.

The results showed that Example 170 inhibited the proliferation of both cell lines, with a greater effect observed after 72 hr compared with 24 hr. In

addition, the recovery experiment showed that neither cell line could recover from the toxicity induced by 24 hr of culture with Example 170.

An additional experiment was done with HL-60 human promyelocytic leukemia in which the inhibition of cellular proliferation by several concentrations of Example 170 were determined after 24 or 72 hrs of culture using the Sulforhodamine B test procedure as described above. Concentrations of Example 170 ranged from 0.005-100  $\mu$ g/ml. The calculated EC<sub>50</sub> value at 24 hr was 2.3  $\mu$ g/ml, and the EC<sub>50</sub> value at 72 hr was 0.1  $\mu$ g/ml.

10

5

15

Table 6
Evaluation of Example 170 in the Sulforhodamine B Standard
Pharmacological Test Procedure with Two Human Leukemia Cell Lines

	Percent of Control						
		Reh Cell	<u>s</u>	CCRF-CEM Cells			
Conc. (µg/ml)	24 hr. Treatment	72 hr Treatment	24 hr Treatment 48 hr Recovery	24 hr Treatment	72 hr Treatment	24 hr Treatment 48 hr Recovery	
0.005	120.15	88.57	105.29	104.86	94.88	152.66	
0.01	110.83	89.43	103.98	111.05	88.98	143.58	
0.05	81.50	71.31	81.23	67.31	19.73	57.05	
0.1	68.67	65.87	84.68	65.48	24.04	38.99	
0.5	67.70	66.24	74.13	65.72	11.59	50.17	
1	83.94	52.91	66.81	51.41	20.74	29.42	
5	66.21	41.86	61.34	30.04	22.24	28.90	
10	71.46	44.70	34.10	42.05	8.17	18.19	
50	55.07	35.40	36.36	47.10	24.84	27.16	
100	84.35	51.62	35.76	113.70	54.07	39.47	
0.2 *	66.99	50.54	39.75	52.44	45.71	20.26	

#### 5 \* Actinomycin-D

## CELL CYCLE ANALYSIS STANDARD PHAMACOLOGICAL TEST PROCEDURE

This standard pharmacological test procedure measures the percentages of cells in a population that are in the G1, S and G2/M phases of the cell cycle. It utilizes staining of fixed cells with propidium iodide and analysis of these cells by flow cytometry. The procedure also gives an estimate of apoptosis induction caused by drug treatment by measurement of the appearance of particles with sub-G1 amounts of DNA. Microtubule-active

drugs characteristically arrest cells in the G2/M phase of the cell cycle because of disruption of the function of the microtubules that comprise the mitotic spindle.

HeLa cells were maintained in RPMI-1640 medium with L-glutamine, supplemented with 10% heat-inactivated fetal calf serum, 100 units/ml penicillin, and 100  $\mu$ g/ml streptomycin. For assay, cells were harvested by trypsinization, washed, counted and distributed to wells of a 6-well plate at 50,000 cells per well in 3 ml of medium. Cells were cultured overnight at 37° in humidified 5% CO<sub>2</sub> in air.

10

15

20

5

On day 2, compounds for test were diluted and added to wells at the final concentrations given in the tables. Twenty hours after drug addition, cells from each well were harvested, fixed with cold 80% ethanol, treated with 100 µg/ml RNAse and stained with propidium iodide before analysis by flow cytometry. The percentages of total cells in G1, S, G2/M, and apoptosis (sub-G1 population) were estimated from the fluorescence histograms, and compared with those determined using untreated control cells in the same assay.

Table 7 displays results for representative compounds of this invention tested at a low concentration and at a five-fold higher concentration. Table 8 displays results of a second experiment in which representative compounds were tested at six concentration levels each. In both experiments the compounds caused a profound increase in the percentage of cells in the G2/M phase of the cell cycle and induced substantial apoptosis.

Table 7

Evaluation of Representative Compounds of the Invention in the Cell Cycle

Analysis Standard Pharmacological Test Procedure with HeLa Cells

Example	Conc.	Percent Cell Cycle Phase						
	(μg/mL)							
		Apop	G1	S	G2/M			
None	-	3	64	18	16			
	_	2	63	18	17			
1	0.84	8	3	10	79			
	4.2	13	7	12	68			
5	0.057	44	10	22	25			
	0.285	9	1	5	85			
7	0.12	8	2	6	84			
	0.6	9	3	8	81			
9	0.86	10	2	7	81			
	4.3	16	28	21	35			
12	0.27	46	10	18	26			
	1.35	7	1	7	85			
27	0.033	28	4	13	55			
	0.165	8	1	5	86			
35	0.022	28	5	14	54			
	0.11	-	_	-	-			
39	2.19	26	4	15	55			
	10.95	19	17	20	45			
41	0.062	9	58	20	13			
	0.31	34	18	17	30			
42	0.33	47	14	20	19			
	1.65	6	1	10	83			
47	0.11	8	2	8	83			
	0.55	7	1	10	81			

Table 7 continued

Example	Conc.	Percent Cell Cycle Phase			
	(μg/mL)				
		Apop	G1	S	G2/M
59	0.18	43	8	24	26
	0.9	8	2	6	84
61	0.08	7	1	9	83
	0.4	7	2	8	83
105	0.08	12	3	11	74
	0.4	6	2	8	84
127	0.08	8	2	12	79
	0.4	6	3	6	84
151	0.08	15	4	14	67
	0.4	9	6	8	76
186	0.08	7	2	8	82
	0.4	7	2	10	80
187	0.08	6	4	9	81
	0.4	7	2	9	81
188	0.08	9	2	8	81
	0.4	9	2	10	78

Note to Table 6: Apop = Apoptosis

Table 8

Evaluation of Representative Compounds of the Invention in the Cell Cycle

Analysis Standard Pharmacological Test Procedure with HeLa Cells

Example	Conc.	Per	Percent Cell Cycle Phase				
	(μg/mL)						
		Apop	G1	S	G2/M		
None	-	4	55	23	18		
	-	3	49	25	20		
	-	1	56	20	20		
35	0.001	1	57	22	20		
	0.003	1	58	22	18		
	0.01	2	57	20	21		
	0.03	29	20	25	25		
	0.1	26	9	13	50		
	0.3	4	4	3	89		
133	0.01	4	54	19	23		
	0.03	28	25	21	25		
	0.1	34	9	26	29		
	0.3	15	5	8	73		
	1	3	4	3	90		
	3	3	4	3	89		
169	0.01	2	51	23	24		
	0.03	14	41	21	24		
	0.1	33	17	23	25		
	0.3	34	8	24	32		
	1	3	5	3	88		
	3	4	5	2	88		

Example	Conc.	Per	cent Cell	Cycle Pha	ase			
	(μg/mL)							
		Apop	G1	S	G2/M			
170	0.01	13	42	21	24			
	0.03	33	17	20	28			
	0.1	27	3	18	50			
	0.3	5	5	4	85			
	1	3	4	4	88			
	3	3	4	4	88			
188	0.001	1	55	21	23			
	0.003	2	56	18	23			
	0.01	18	35	19	27			
	0.03	27	7	14	52			
	0.1	4	4	3	88			
	0.3	3	3	3	90			
208	0.001	2	59	20	20			
	0.003	2	57	20	21			
	0.01	14	43	20	23			
	0.03	33	8	21	36			
	0.1	3	2	3	90			
	0.3	3	3	2	91			

Note to Table 7: Apop = Apoptosis

10

15

25

30

# TUBULIN POLYMERIZATION STANDARD PHARMACOLOGICAL TEST PROCEDURE USING HIGHLY PURIFIED TUBULIN

This standard pharmacological test procedure determines the activity of representative compounds of this invention in promoting the polymerization of  $\alpha/\beta$  tubulin heterodimers. The tubulin preparation used was over 99% pure so that any effects of test compounds on polymerization must be due to direct binding of the test compounds to tubulin protein. It is well known that in this assay paclitaxel promotes polymerization compared to the control reaction without drug, and that vincristine and colchicine inhibit polymerization. Highly purified tubulin does not exhibit substantial spontaneous polymerization at protein concentrations between 1 and 2 mg/ml. Therefore an agent such as glycerol is added to the reactions to lower the critical concentration for polymerization and yield a higher spontaneous control polymerization. In some experiments described below, either glycerol or guanosine 5'-triphosphate (the energy source of polymerization) was left out of the reaction mixtures in order to better compare the effects of paclitaxel and representative compounds of this invention.

### 20 Part 1. Polymerization of Purified Tubulin in the Presence of Guanosine 5'-triphosphate and Glycerol

Bovine brain tubulin, purchased from Cytoskeleton, Inc., was greater than 99% pure by polyacrylamide gel electrophoresis. The protein was dissolved at 1.5 mg/ml in ice-cold GPEM buffer (80 mM piperazine-N,N'-bis[2-ethanesulfonic acid], pH 6.9, 1 mM ethylene glycol-bis(ß-aminoethyl ether)-N,N,N',N'-tetraacetic acid, 1 mM magnesium chloride, 1 mM guanosine 5'-triphosphate, GTP) containing 10% (w/w) glycerol. The solution was centrifuged at top speed in an Eppendorf model 5415C microfuge for 10 min at 4° immediately before use. The tubulin solution was added to wells of a ½ area 96-well plate (Costar No. 3696) already containing the compounds of

15

interest. Each compound was assayed at three concentrations as indicated. Final volume per well was 110 µl. Each sample was done in duplicate, and the control reaction, which received drug solvent only, was done in quadruplicate. The highest concentration of DMSO in any reaction was 1%.

The plate was put in a Molecular Devices SpectraMax plate reader thermostated at 35° and the absorbance of each well at 340 nm was determined every minute for 60 minutes. The absorbance at time 0 for each well was subtracted from each of the subsequent absorbance readings for that well, and then the duplicates were averaged.

The results of this standard pharmacological test procedure with representative compounds of this invention and with standard microtubule-active drugs are displayed in Tables 9 to 14. Compounds that enhanced the rate and/or extent of purified tubulin polymerization compared to the control (as does paclitaxel) were judged to be promoters of polymerization; compounds that reduced the rate or extent of polymerization (e.g., vincristine, colchicine) were judged to be inhibitors.

Table 9
Evaluation of Examples 35 and 188 in the Tubulin Polymerization
Standard Pharmacological Test Procedure

				$\Delta A_{340}$			
	I	Example 3	5	E	3	Control	
Time (min)	10 μΜ	1 μΜ	0.1 μΜ	10 μΜ	1 μΜ	0.1 μΜ	
0	0	0	0	0	0	0	0
5	0.0434	0.0003	0.0004	0.0179	-0.0007	-0.0006	-0.0009
10	0.0972	0.0015	0.0010	0.0469	0.0001	-0.0005	-0.0008
15	0.1219	0.0028	0.0012	0.0667	0.0016	-0.0001	0.0001
20	0.1316	0.0058	0.0024	0.0813	0.0040	0.0009	0.0019
25	0.1364	0.0079	0.0041	0.0919	0.0063	0.0026	0.0051
30	0.1387	0.0106	0.0061	0.0988	0.0110	0.0052	0.0087
35	0.1397	0.0139	0.0079	0.1032	0.0141	0.0079	0.0132
40	0.1401	0.0177	0.0099	0.1064	0.0179	0.0119	0.0198
45	0.1392	0.0232	0.0133	0.1100	0.0229	0.0142	0.0221
50	0.1396	0.0278	0.0167	0.1149	0.0288	0.0203	0.0245
55	0.1399	0.0311	0.0193	0.1165	0.0337	0.0262	0.0282
60	0.1398	0.0350	0.0224	0.1176	0.0372	0.0304	0.0340

Table 10

Evaluation of Example 170 and Paclitaxel in the Tubulin Polymerization

Standard Pharmacological Test Procedure

				$\Delta A_{340}$			
		Example 1	70			Control	
Time (min)	10 μΜ	1 μΜ	0.1 μΜ	10 μΜ	1 μΜ	0.1 μΜ	
0	0	0	0	0	0	0	0
5	0.0103	-0.0001	-0.0005	0.0136	0.0044	-0.0012	-0.0009
10	0.0555	0.0008	-0.0010	0.0416	0.0167	-0.0010	-0.0008
15	0.0923	0.0028	-0.0005	0.0704	0.0336	0.0001	0.0001
20	0.1100	0.0056	0.0002	0.0931	0.0500	0.0025	0.0019
25	0.1199	0.0093	0.0018	0.1075	0.0638	0.0060	0.0051
30	0.1257	0.0143	0.0041	0.1162	0.0748	0.0100	0.0087
35	0.1289	0.0198	0.0053	0.1216	0.0835	0.0123	0.0132
40	0.1330	0.0246	0.0088	0.1245	0.0903	0.0168	0.0198
45	0.1353	0.0291	0.0124	0.1269	0.0957	0.0229	0.0221
50	0.1353	0.0338	0.0155	0.1279	0.0997	0.0257	0.0245
55	0.1363	0.0380	0.0192	0.1279	0.1027	0.0293	0.0282
60	0.1364	0.0419	0.0241	0.1282	0.1053	0.0314	0.0340

Table 11

Evaluation of Examples 169 and 175 in the Tubulin Polymerization

Standard Pharmacological Test Procedure

				_			
				Δ <b>A</b> <sub>340</sub>			
	[	Example	169	E	xample 1	75	Control
Time (min)	10 μM	1 μΜ	0.1 μΜ	10 μΜ	1 μΜ	0.1 μΜ	
0	0	0	0	0	0	0	0
5	0.0239	0.0005	-0.0014	0.0073	0.0001	-0.0012	-0.0012
10	0.1172	0.0011	-0.0009	0.0199	0.0014	-0.0005	-0.0011
15	0.1435	0.0024	0.0001	0.0309	0.0037	0.0011	0.0000
20	0.1509	0.0045	0.0020	0.0399	0.0067	0.0025	0.0024
25	0.1532	0.0073	0.0042	0.0488	0.0102	0.0057	0.0051
30	0.1548	0.0106	0.0057	0.0566	0.0160	0.0088	0.0108
35	0.1554	0.0154	0.0105	0.0638	0.0217	0.0116	0.0157
40	0.1555	0.0197	0.0136	0.0704	0.0294	0.0177	0.0203
45	0.1552	0.0246	0.0186	0.0761	0.0349	0.0233	0.0246
50	0.1545	0.0331	0.0234	0.0817	0.0416	0.0261	0.0329
55	0.1561	0.0414	0.0282	0.0872	0.0450	0.0309	0.0369
60	0.1552	0.0456	0.0322	0.0919	0.0485	0.0373	0.0392

Table 12

Evaluation of Example 178 and Paclitaxel in the Tubulin

Polymerization Standard Pharmacological Test Procedure

	·						
				$\Delta A_{340}$			
	Е	xample 17	'8		Paclitaxel		Control
Time (min)	10 μΜ	1·μM	0.1 μM	10 μΜ	1 μΜ	0.1 μΜ	
0	0	0	0	0	0	0	0
5	0.0182	-0.0029	-0.0001	0.0200	0.0024	-0.0008	-0.0012
10	0.0304	-0.0021	0.0000	0.0587	0.0144	0.0005	-0.0011
15	0.0448	-0.0007	0.0002	0.0939	0.0315	0.0031	0.0000
20	0.0602	0.0006	0.0009	0.1199	0.0484	0.0070	0.0024
25	0.0770	0.0039	0.0030	0.1369	0.0626	0.0103	0.0051
30	0.0951	0.0064	0.0055	0.1470	0.0746	0.0159	0.0108
35	0.1099	0.0110	0.0080	0.1522	0.0838	0.0197	0.0157
40	0.1250	0.0152	0.0134	0.1557	0.0913	0.0256	0.0203
45	0.1360	0.0202	0.0216	0.1583	0.0969	0.0304	0.0246
50	0.1424	0.0242	0.0218	0.1584	0.1014	0.0336	0.0329
55	0.1488	0.0273	0.0229	0.1588	0.1050	0.0368	0.0369
60	0.1538	0.0316	0.0299	0.1586	0.1076	0.0399	0.0392

Table 13

Evaluation of Examples 198 and 211 and Paclitaxel in the Tubulin Polymerization Standard Pharmacological Test Procedure

		$\Delta A_{340}$									
	E	Example 198			Example 211			Paclitaxel			
*	10 μM	1 μM	0.1 μM	10 μΜ	1 μM	0.1 μM	10 μМ	1 μM	0.1 μM		
0	0	0	0	0	0	0	0	0	0	0	
5	0.0011	0.0001	0.0021	-0.0008	-0.0019	-0.0001	0.0145	0.0037	-0.0014	-0.0012	
10	0.0025	0.0006	0.0053	-0.0006	-0.0017	0.0014	0.0496	0.0173	0.0032	-0.0014	
15	0.0057	0.0017	0.0096	0.0009	0.0000	0.0043	0.0857	0.0381	0.0056	-0.0001	
20	0.0117	0.0046	0.0143	0.0029	0.0027	0.0080	0.1119	0.0572	0.0098	0.0031	
25	0.0206	0.0071	0.0200	0.0055	0.0060	0.0129	0.1280	0.0731	0.0160	0.0077	
30	0.0303	0.0106	0.0239	0.0085	0.0107	0.0173	0.1370	0.0860	0.0217	0.0124	
35	0.0407	0.0153	0.0292	0.0121	0.0138	0.0228	0.1427	0.0961	0.0289	0.0193	
40	0.0489	0.0214	0.0367	0.0165	0.0195	0.0287	0.1462	0.1041	0.0360	0.0223	
45	0.0572	0.0258	0.0393	0.0211	0.0251	0.0321	0.1483	0.1102	0.0431	0.0288	
50	0.0661	0.0320	0.0495	0.0263	0.0279	0.0397	0.1495	0.1148	0.0488	0.0345	
55	0.0729	0.0360	0.0556	0.0320	0.0339	0.0458	0.1505	0.1185	0.0544	0.0389	
60	0.0763	0.0413	0.0607	0.0383	0.0393	0.0512	0.1508	0.1211	0.0596	0.0440	

<sup>\*</sup> Time (min)

<sup>\*\*</sup> Control

Table 14

Evaluation of Vincristine, Colchicine, and Paclitaxel in the Tubulin Polymerization Standard Pharmacological Test Procedure

					ΔΑ	340	· · · · · · · · · · · · · · · · · · ·			
	\	/incristin	е	(	Colchicine	9	Paclitaxel			**
*	10 μΜ	1 μΜ	0.1 μΜ	10 μΜ	1 μΜ	0.1 μΜ	10 μΜ	1 μΜ	0.1 μΜ	
0	0,	0	0	0	0	0	0	0	0	0
5	-0.0011	-0.0008	0.0016	0.0005	-0.0003	-0.0011	0.0104	0.0023	-0.0008	-0.0016
10	0.0001	-0.0007	0.0012	0.0011	0.0000	-0.0012	0.0372	0.0128	0.0020	-0.0013
15	-0.0001	-0.0007	0.0018	0.0006	0.0002	-0.0008	0.0658	0.0288	0.0084	0.0007
20	-0.0006	-0.0001	0.0031	-0.0001	0.0009	0.0003	0.0885	0.0434	0.0107	0.0027
25	-0.0012	0.0003	0.0044	-0.0003	0.0019	0.0024	0.1040	0.0568	0.0160	0.0054
30	-0.0015	0.0012	0.0074	-0.0008	0.0029	0.0058	0.1149	0.0682	0.0251	0.0103
35	-0.0018	0.0019	0.0119	-0.0008	0.0039	0.0086	0.1218	0.0779	0.0321	0.0181
40	-0.0017	0.0029	0.0154	-0.0012	0.0044	0.0119	0.1261	0.0857	0.0366	0.0232
45	-0.0020	0.0041	0.0189	-0.0016	0.0057	0.0159	0.1299	0.0920	0.0423	0.0272
50	-0.0025	0.0057	0.0253	-0.0020	0.0067	0.0209	0.1313	0.0975	0.0480	0.0300
55	-0.0026	0.0067	0.0298	-0.0020	0.0079	0.0243	0.1325	0.1015	0.0517	0.0362
60	-0.0026	0.0079	0.0322	-0.0021	0.0090	0.0274	0.1335	0.1049	0.0550	0.0399

<sup>\*</sup> Time (min)

<sup>\*\*</sup> Control

### Part 2.Polymerization of Purified Tubulin in the Absence of Either Guanosine 5'-triphosphate or Glycerol

This standard pharmacological test procedure measures the ability of a representative example of the invention to induce polymerization of purified tubulin in the absence of glycerol or guanosine 5'-triphosphate (GTP). All other conditions and data calculation were as given above in Part 1.

In the first experiment, the polymerization reaction mixture did not contain glycerol. In the absence of glycerol, highly purified tubulin undergoes very little spontaneous polymerization but paclitaxel is known to induce polymerization under these conditions. The data displayed in Table 15 show that Example 170 also induced polymerization in the absence of glycerol.

In the second experiment, GTP was absent from the reaction mixture. Normal tubulin polymerization requires energy released from GTP hydrolysis to drive subunit assembly, but paclitaxel is able to induce polymer formation even in the absence of GTP. The data displayed in Table 16 show that Example 170 also induced polymerization in the absence of GTP.

The results of both these experiments are consistent with the conclusion that Example 170 has a paclitaxel-like mechanism of action on tubulin polymerization.

20

5

10

Table 15

Evaluation of Example 170 and Paclitaxel in the Tubulin Polymerization Standard Pharmacological Test Procedure in the absence of glycerol

			$\Delta A_{340}$									
Time			△/~340									
(min)												
	Examp	le 170	Pacli	taxel	<u>Control</u>							
	10 μΜ	1 μΜ	10 μΜ	1 μΜ								
0	0	0	0	0	0							
5	0.0019	0.0005	0.0056	0.0014	0.0002							
10	0.0049	0.0014	0.0279	0.0091	0.0007							
15	0.0095	0.0024	0.0546	0.0198	0.0011							
20	0.0153	0.0039	0.0801	0.0310	0.0018							
25	0.0215	0.0054	0.1016	0.0412	0.0024							
30	0.0280	0.0074	0.1188	0.0500	0.0033							
35	0.0347	0.0097	0.1070	0.0576	0.0043							
40	0.0422	0.0121	0.1142	0.0638	0.0048							
45	0.0504	0.0149	0.1192	0.0691	0.0058							
50	0.0595	0.0188	0.1238	0.0737	0.0069							
55	0.0687	0.0222	0.1262	0.0773	0.0077							
60	0.0783	0.0264	0.1293	0.0805	0.0094							

Table 16

Evaluation of Example 170 and Paclitaxel in the Tubulin Polymerization Standard Pharmacological Test Procedure in the absence of GTP

			Α Λ									
Time		•	$\Delta A_{340}$									
(min)												
	Examp	le 170	Pacli	taxel	<u>Control</u>							
	20 μΜ	5 μΜ	20 μΜ	5 μΜ								
0	0	0	0	0	0							
5	0.0364	0.0000	0.0204	0.0032	-0.0010							
10	0.0582	0.0009	0.0592	0.0160	-0.0004							
15	0.0735	0.0028	0.0933	0.0305	0.0019							
20	0.0830	0.0046	0.1159	0.0445	0.0035							
25	0.0921	0.0078	0.1288	0.0570	0.0078							
30	0.1022	0.0107	0.1365	0.0674	0.0121							
35	0.1086	0.0142	0.1409	0.0764	0.0167							
40	0.1125	0.0180	0.1435	0.0843	0.0198							
45	0.1192	0.0220	0.1449	0.0908	0.0241							
50	0.1225	0.0265	0.1457	0.0962	0.0276							
55	0.1264	0.0310	0.1456	0.1008	0.0333							
60	0.1277	0.0357	0.1455	0.1046	0.0387							

## IMMUNOFLUORESCENCE STANDARD TEST PROCEDURE FOR ANALYSIS OF EFFECTS OF COMPOUNDS ON MORPHOLOGY OF MITOTIC SPINDLE MICROTUBULES IN CELLS

5

10

.

15

20

25

Compounds that bind to tubulin or microtubules typically have profound and characteristic effects on the structure of the microtubules which comprise the mitotic spindle of dividing cells. Compounds such as vincristine and colchicine that inhibit normal tubulin polymerization cause a severe disruption and even disappearance of spindle microtubules. On the other hand, compounds such as paclitaxel that promote tubulin polymerization and stabilize microtubules cause the appearance of dense tubulin bundles or aggregates. These effects of compounds can be visualized by immunofluorescent staining of fixed cells.

PC-3 MM2 human prostate carcinoma cells were plated at 5 X 10<sup>4</sup> cells/chamber in 8-chamber microscope slides that had been treated with poly-D-lysine (Biocoat 8-well CultureSlide, Becton Dickinson). The cells were allowed to attach and grow for 24 hr before addition of compounds at the indicated concentrations. After an additional 18-20 hr of culture with compounds, cells were fixed directly on the slides with methanol at minus 20°, rehydrated in phosphate-buffered saline, and stained with a mouse monoclonal antibody to α-tubulin (clone DM 1A, Sigma) followed by F(ab')<sub>2</sub> fragments of goat anti-mouse IgG, FITC conjugate (Jackson Immunoresearch). Cells were also stained with Hoescht 33258 to visualize DNA. Cells were viewed with a Zeiss fluorescence microscope under epi-illumination, and digital images were captured with a MTI Model DC330 video camera using Optimas V software. Images were processed using Corel PhotoPaint.

As displayed in Table 17, representative compounds or this invention produced marked bundling or aggregation of spindle microtubules in dividing

10

cells. The patterns of microtubule bundling were similar to that produced by paclitaxel. When tested at equi-potent concentrations (i.e., at a concentration of each compound equal to eight times its IC<sub>50</sub> value in the 3-day MTS cytotoxicity assay), paclitaxel produced predominantly bipolar structures in which the microtubules appeared to be shortened and condensed. The compounds of this invention typically produced two, three, or four dense, circular bundles with intense fluorescence. The microtubule disrupting agents, vincristine and colchicine, produced patterns that were quite distinct from the compounds described here. These results are consistent with the conclusion that the compounds of this invention promote tubulin polymerization, as does paclitaxel.

Table 17

Evaluation of Representative Compounds of this Invention on Morphology of Mitotic Spindle Microtubules in PC-3 MM2 Cells Determined by the Immunofluorescence Standard Pharmacological Test Procedure

Ex.	Concentration	Appearance of Mitotic Spindle Microtubules
	(μ <b>M</b> )	
35	0.54	Less tightly condensed, greater variety of abnormal
		structures, including "tangled spaghetti"
169	6.41	Dense, compact, highly fluorescent bundles, roughly
		circular in shape, 2-4 per cell
170	1.74	Dense, compact, highly fluorescent bundles, roughly
		circular in shape, 2-4 per cell
175	0.74	Dense, compact, highly fluorescent bundles, roughly
		circular in shape, 2-4 per cell
178	1.91	Rigid spikes emanating from a central core: "sea urchin"
		appearance
188	0.24	Dense, compact, highly fluorescent bundles, roughly
		circular in shape, 2-4 per cell
198	2.10	Dense, compact, highly fluorescent bundles, roughly
		circular in shape, 2-4 per cell
208	0.26	Dense, compact, highly fluorescent bundles, roughly
		circular in shape, up to 8 per cell
211	0.89	Dense, compact, highly fluorescent bundles, roughly
		circular in shape, 2-4 per cell
Paclitaxel	0.016	Dense, compact, highly fluorescent bundles, typically
		bipolar
Vincristine	0.008	Multiple abnormal structures, many resembling partially
		disrupted spindles
Colchicine	0.064	Almost completely depolymerized microtubules,
		sometimes with multiple small flecks of brighter
		fluorescence

10

15

### STANDARD PHARMACOLOGICAL TEST PROCEDURE OF ANTITUMOR ACTIVITY IN ATHYMIC MICE BEARING HUMAN TUMOR XENOGRAFTS

The tumors used were H157 human non-small cell lung carcinoma, U87MG human glioblastoma, LOX human melanoma, and DLD1 human colon adenocarcinoma. Cells were cultured in RPMI-1640 medium with L-glutamine, supplemented with 10% heat-inactivated fetal calf serum, 100 units/ml penicillin and 100  $\mu$ g/ml streptomycin. Cells were injected subcutaneously into the flank of outbred nu/nu mice. About 5 days later tumors were staged and those around 100 mg were selected for use. Tumor weights were calculated from measurements of length in two dimensions.

Compounds for test were prepared in Klucel and administered to mice by intraperitoneal injection (0.5 ml volume) or by oral gavage (0.2 ml volume). Typically, the compounds of this invention were given twice per day for 14 days at the doses indicated in the tables. Each experimental group contained 10 animals unless otherwise indicated. The control group (also 10 animals) received Klucel only. Tumor weights were estimated every 3 to 5 days in most experiments (every 7 days in one experiment).

Individual experiments are displayed in Tables 18-28.

Table 18

Evaluation of Example 170 on Growth of Human H157 Non-small
Cell Lung Carcinoma in Athymic Mice: Comparison of
Intraperitoneal and Oral Dosing

		•						
Treatment	Parameter	Day 0	Day 7	Day 10	Day 14	Day 16	Day	Day 21
							18	
Klucel	MTW	121	509	756	1298	1583	1752	2879
Ex. 170	MTW	128	221	287	567	755	1163	2467
25 mg/kg								
bid, ip								
	T/C	1.05	0.43	0.38	0.44	0.48	0.66	0.86
	р		0.001	0.001	0.001	0.009	0.062	0.282
Ex. 170	MTW	125	191	235	489	591	816	1835
25 mg/kg								
bid, po								
	T/C	1.03	0.37	0.31	0.38	0.37	0.47	0.64
	р		0.0005	0.0003	0.0003	0.0025	0.0065	0.052

- 1. MTW = mean tumor weight = mean weight of tumors in all animals of the group. Each group had 10 animals.
- 10 2. Animals were staged on day 0 and dosed on days 1-14.
  - 3. T/C = MTW of treated animals on day n/MTW of control animals on day n.
  - 4. p = p value, Student's T-test.
  - 5. No deaths in experimental groups.

# Table 19 Evaluation of Example 170 on Growth of Human H157 Non-small Cell Lung Carcinoma in Athymic Mice: Comparison of Oral Dosing at Three Levels

Treatment	Parameter	Day 0	Day 4	Day 8	Day 12	Day 14	Day 17
Klucel	MTW	117	270	549	1066	1632	2314
Ex. 170	MTW	127	142	194	428	602	839
25 mg/kg							
bid, po							
	T/C	1.08	0.53	0.35	0.40	0.37	0.36
	р		0.002	0.001	0.003	0.001	0.001
Ex. 170	MTW	126	188	275	464	748	965
12.5 mg/kg							
bid, po							
	T/C	1.08	0.70	0.50	0.44	0.46	0.42
	р		0.018	0.005	0.004	0.004	0.002
Ex. 170	MTW	121	221	377	643	1030	1147
6.3 mg/kg							
bid, po							
	T/C	1.03	0.82	0.69	0.60	0.63	0.50
	р		0.130	0.044	0.023	0.024	0.003

5

- 1. MTW = mean tumor weight = mean weight of tumors in all animals of the group. Each group had 10 animals.
- 2. Animals were staged on day 0 and dosed on days 1-14.
- 10 3. T/C = MTW of treated animals on day n/MTW of control animals on day n.
  - 4. p = p value, Student's T-test.
  - 5. One death each in 25 and 12.5 groups.

Table 20

Evaluation of Example 170 on Growth of Human H157 Non-small Cell

Lung Carcinoma in Athymic Mice:

Comparison of Oral Dosing Once or Twice Per Day

Treatment	Parameter	Day 0	Day 4	Day 9	Day 12	Day 14	Day 18
Klucel	MTW	111	334	577	1037	2237	3782
	A STIAL	400	240	287	431	766	1550
Ex. 170 25 mg/kg qd, po	MTW	126	219	287	431	700	1330
	T/C	1.14	0.65	0.50	0.42	0.34	0.41
	р		0.03	0.01	0.0006	0.0006	0.005
Ex. 170 25 mg/kg bid, po	MTW	115	123	158	176	413	817
	T/C	1.04	0.37	0.27	0.17	0.18	0.22
	р		4E-05	5E-05	2E-06	9E-06	2.5E-05

- 1. MTW = mean tumor weight = mean weight of tumors in all animals of the group. Each group had 10 animals.
- 10 2. Animals were staged on day 0 and dosed on days 1-14.
  - 3. T/C = MTW of treated animals on day n/MTW of control animals on day n.
  - 4. p = p value, Student's T-test.
  - 5. No deaths in experimental groups.

Table 21

Evaluation of Example 170, Example 169, and Example 133 on

Growth of Human H157 Non-small Cell Lung Carcinoma in Athymic

Mice:

Treatment	Parameter	Day 0	Day 5	Day 7	Day 10	Day 14	Day 17
Klucel	MTW	119	300	425	638	1385	1940
Ex. 170 25 mg/kg	MTW	136	215	253	345	540	1203
bid, ip							
,	T/C	1.14	0.72	0.60	0.54	0.39	0.62
	р		0.07	0.05	0.07	0.03	0.10
Ex. 169	MTW	136	277	425	716	1641	1869
25 mg/kg							
bid, ip							
	T/C	1.14	0.92	1.00	1.12	1.18	0.96
				ļ			
Ex. 133	MTW	139	262	367	558	1103	1888
25 mg/kg bid, ip			*				
	T/C	1.17	0.87	0.86	0.87	0.80	0.97

- 1. MTW = mean tumor weight = mean weight of tumors in all animals of the group. Each group had 10 animals.
- 10 2. Animals were staged on day 0 and dosed on days 1-14.
  - 3. T/C = MTW of treated animals on day n/MTW of control animals on day n.
  - 4. p = p value, Student's T-test.
  - 5. One death in Example 170 group.

Table 22

Evaluation of Example 170 and Example 208 on Growth of Human H157

Non-small Cell Lung Carcinoma in Athymic Mice

Treatment	Parameter	Day 0	Day 3	Day 7	Day 10	Day 14	Day 17	Day 21
Klucel	MTW	138	213	580	1028	1948	3041	3453
					<u> </u>			
Ex. 170	MTW	159	123	162	236	391	562	1335
50 mg/kg bid, then qd, ip								
	T/C	1.15	0.58	0.28	0.23	0.20	0.18	0.39
	р		0.002	0.0005	0.001	0.001	0.0005	0.006
Ex. 208	MTW	158	187	287	367	See	See	See
50 mg/kg						note 5	note 5	note 5
bid, then qd,ip								

- 1. MTW = mean tumor weight = mean weight of tumors in all animals of the group. Each group had 10 animals.
- 2. Animals were staged on day 0 and dosed on days 1-14. Dosing was bid days 1-6, then qd days 7-14.
  - 3. T/C = MTW of treated animals on day n/MTW of control animals on day n.
  - 4. p = p value, Student's T-test.
  - 5. Dosing of Example 208 was stopped after 10 days because of toxicity.
- 15 6. 1 death in Example 170 group.

Table 23

Evaluation of Example 35 on Growth of Human H157

Non-small Cell Lung Carcinoma in Athymic Mice

Treatment	Parameter	Day 0	Day 6	Day 10	Day 14	Day 18	Day 21	Day 25
Klucel	MTW	87	255	334	721	1212	1148	2076
Ex. 35 50 mg/kg bid, ip	MTW	91	305	514	1372	2192	2296	2154
olu, ip	T/C p	1.05	1.20	1.54	1.90	1.81	2.00	1.04

- 1. MTW = mean tumor weight = mean weight of tumors in all animals of the group. Each group had 10 animals.
- 2. Animals were staged on day 0 and dosed on days 1-14
- 10 3. T/C = MTW of treated animals on day n/MTW of control animals on day n.
  - 4. p = p value, Student's T-test.
  - 5. No deaths in experimental group.

Table 24

Evaluation of Example 188 on Growth of Human H157 Non-small Cell Lung Carcinoma in Athymic Mice

Treatment	Parameter	Day 0	Day 4	Day 7	Day 10
Klucel	MTW	139	325	516	942
			-		
Ex. 188 50 mg/kg bid, ip	MTW	154	385	560	1037
	T/C	1.11	1.18	1.08	1.10
	р		0.15	0.33	0.31

- 1. MTW = mean tumor weight = mean weight of tumors in all animals of the group. Each group had 10 animals.
- 10 2. Animals were staged on day 0 and dosed on days 1-10.
  - 3. T/C = MTW of treated animals on day n/MTW of control animals on day n.
  - 4. p = p value, Student's T-test.
  - 5. Dosing of Example 188 was stopped after 10 days because of toxicity.

Table 25
Evaluation of Example 170 on Growth of Human U87MG
Glioblastoma in Athymic Mice: Comparison of Intraperitoneal
Dosing at Three Levels

Treatment	Parameter	Day 0	Day 4	Day 7	Day 10	Day 14	Day 17	Day 19
Klucel	MTW	160	258	406	504	1025	1656	2257
Ex. 170	MTW	156	134	145	111	144	200	296
25 mg/kg								
bid, ip								
	T/C	0.98	0.52	0.36	0.22	0.14	0.12	0.13
	р		2E-07	8.8E-07	1.5E-08	6.9E-09	3.3E-09	2.8E-06
Ex. 170	MTW	156	190	232	314	664	1155	1896
10 mg/kg								
bid, ip								
	T/C	0.98	0.74	0.57	0.62	0.65	0.70	0.84
	р		0.0010	0.0001	0.0005	0.0027	0.0084	0.174
Ex. 170	MTW	161	213	320	414	849	1631	2567
5 mg/kg								
bid, ip								
	T/C	1.01	0.83	0.79	0.82	0.83	0.99	1.14
	р		0.028	0.052	0.100	0.157	0.462	0.259

- 1. MTW = mean tumor weight = mean weight of tumors in all animals of the group. Each group had 10 animals.
- 10 2. Animals were staged on day 0 and dosed on days 1-14.
  - 3. T/C = MTW of treated animals on day n/MTW of control animals on day n.
  - 4. p = p value, Student's T-test.
  - 5. No deaths in experimental groups.

Table 26
Evaluation of Representative Compounds of this Invention on
Growth of Human U87MG Glioblastoma in Athymic Mice

Treatment	Parameter	Day 0	Day 3	Day 7	Day 9
Klucel	MTW	128	213	363	537
	,				
Ex. 170	MTW	128	138	120	112
25 mg/kg					
bid, ip					
	T/C	1.00	0.65	0.33	0.21
Ex. 211	MTW	130	171	266	374
25 mg/kg		1 1			
bid, ip					
	T/C	1.02	0.80	0.73	. 0.70
Ex. 198	MTW	127	198	305	559
25 mg/kg		ļ			
bid, ip	·				
	T/C	0.99	0.93	0.84	1.04
Ex. 178	MTW	124	112	See	See
25 mg/kg				note 4	note 4
bid, ip					
	T/C	0.97	0.53		

Table 26 Continued

Evaluation of Representative Compounds of this Invention on Growth of

Human U87MG Glioblastoma in Athymic Mice

Treatment	Parameter	Day 0	Day 3	Day 7	Day 9
Klucel	MTW	128	213	363	537
Ex. 175	MTW	138	176	239	433
25 mg/kg					
bid, ip					
	T/C	1.08	0.83	0.66	0.81
Ex. 35	MTW	135	180	226	427
25 mg/kg					
bid, ip					
	T/C	1.05	0.85	0.62	0.80
Ex. 169	MTW	136	187	254	464
25 mg/kg					
bid, ip					
	T/C	1.06	0.88	0.70	0.86

- 1. MTW = mean tumor weight = mean weight of tumors in all animals of the group. Each group had 10 animals.
- 10 2. Animals were staged on day 0 and dosed on days 1-9.
  - 3. T/C = MTW of treated animals on day n/MTW of control animals on day n.
  - 4. Dosing of Example 178 was stopped after 4 days because of toxicity.

Table 27

Evaluation of Example 170 on Growth of Human LOX Melanoma in Athymic Mice: Comparison of Intraperitoneal and Oral Dosing

Treatment	Parameter	Day 0	Day 7	Day 14
Klucel	RTG	1	11.51	40.53
Ex. 170	RTG	1	4.91	14.77
25 mg/kg				
bid, ip				
	T/C	1	0.43	0.36
	р		0.05	0.08
Ex. 170	RTG	1	8.06	35.55
10 mg/kg				
bid, ip				
	T/C		0.70	0.88
	р		0.38	0.53
Ex. 170	RTG	1	10.17	40.49
25 mg/kg				
bid, po				
	T/C		0.88	1.00
	р		0.61	0.53

- 1. RTG = relative tumor growth = mean tumor weight on day n/mean tumor weight of same group on day 0. 10 animals in control group, 5 in CL 376894 groups.
- 10 2. Animals were staged on day 0 and dosed on days 1-14.
  - 3. T/C = RTG of treated animals on day n/RTG of control animals on day n.
  - 4. p = p value, Student's T-test.
  - 5. No deaths in experimental groups.

Table 28
Evaluation of Example 170 on Growth of Human DLD1 Colon
Carcinoma in Athymic Mice: Comparison of Intraperitoneal and
Oral Dosing

Treatment	Parameter	Day 0	Day 7	Day 14	Day 21
Klucel	RTG	1	3.17	9.62	18.11
Ex. 170	RTG	1	3.60	8.08	14.58
25 mg/kg					
bid, ip	,				
	T/C		1.14	0.84	0.81
	р		0.87	0.20	0.31
Ex. 170	RTG	1	3.95	9.64	17.32
25 mg/kg					:
bid, po					
	T/C		1.25	1.00	0.96
	р		0.96	0.56	0.48

- 1. RTG = relative tumor growth = mean tumor weight on day n/mean tumor weight of same group on day 0. Each group had 10 animals.
- 10 2. Animals were staged on day 0 and dosed on days 1-14.
  - 3. T/C = RTG of treated animals on day n/RTG of control animals on day n.
  - 4. p = p value, Student's T-test.
  - 5. No deaths in experimental groups.

10

15

20

25

30

Based on the results of these standard pharmacological test procedures, the compounds of this invention are useful as agents for treating, inhibiting or controlling the growth of cancerous tumor cells and associated diseases in a mammal in need thereof by interacting with tubulin and microtubules and promotion of microtubule polymerization. The compounds of the invention are also useful for the treaatment or prevention of multiple drug resistant (MDR). The effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration and severity of the condition being treated. However, in general satisfactory results are obtained when the compounds of the invention are administered in amounts ranging from about 0.10 to about 100 mg/kg of body weight per day. A preferred regimen for optimum results would be from about 1 mg to about 20 mg/kg of body weight per day and such dosage units are employed that a total of from about 70 mg to about 1400 mg of the active compound for a subject of about 70 kg of body weight are administered in a 24 hour period.

The dosage regimen for treating mammals may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. A decidedly practical advantage is that these active compounds may be administered in any convenient manner such as by the oral, intravenous, intramuscular or subcutaneous routes. The active compounds may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or they may be enclosed in hard or soft shell gelatin capsules, or they may be compressed into tablets or they may be incorporated directly with the food of the diet. For oral therapeutic administration, these active compounds may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers and the like. Such compositions and preparations should contain at least 0.1% of active compound. The percentage of the compositions and preparations may, of course, be varied

10

15

20

25

30

and may conveniently be between about 2% to about 60% of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that a suitable dosage will be obtained. Preferred compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains between 10 and 1000 mg of active compound.

The tablets, troches, pills, capsules and the like may also contain the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose, or saccharin may be added or a flavoring agnet such as peppermint, oil of wintergreen or cherry flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills or capsules may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, sucrose, as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts used. In addition, these active compounds may be incorporated into sustained-release preparations and formulations.

These active compounds may also be administered parenterally or intraperitoneally. Solutions or suspensions of these active compounds as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth or microorganisms.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and starage and must be prepared against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid poly-ethylene glycol), suitable mixtures thereof, and vegetable oils.

10

5

The following examples are representative compounds of this invention which are useful as promoters of microtubule polymerization and as anticancer agents.

#### Example 1

15

7-(1-azepanyl)-5-chloro-6-phenyl[1,2,4]triazolo[1,5-a]pyrimidine

#### Example 2

### 5-chloro-6-(2,6-difluorophenyl)-7-(4-methyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine

20

#### Example 3

5-chloro-6-(4-methoxyphenyl)-7-(1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine

#### Example 4

25

5-chloro-6-(2-chloro-6-fluorophenyl)-7-(4-methyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine

#### Example 5

7-(1-azepanyl)-5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine

## <u>Example 6</u> <u>5-chloro-6-(2-chloro-6-fluorophenyl)-7-(2-methyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine</u>

5	Example 7
	5-chloro-6-(2-chloro-6-fluorophenyl)-7-(4-thiomorpholinyl)[1,2,4]triazolo[1,5-
	<u>a]pyrimidine</u>
	Example 8
10	methyl [[5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-
	yl](methyl)amino]acetate
	Example 9
	5-chloro-6-(2-chloro-6-fluorophenyl)-N-(1,1,3,3-
15	tetramethylbutyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
	Example 10
	7-(1-azepanyl)-5-chloro-6-(4-methoxyphenyl)[1,2,4]triazolo[1,5-a]pyrimidine
20	Example 11
	7-(1-azepanyl)-6-(4-bromophenyl)-5-chloro[1,2,4]triazolo[1,5-a]pyrimidine
	,
	Example 12
	5-chloro-7-(1-piperidinyl)-6-[2-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-
25	<u>a]pyrimidine</u>
	Example 13
	6-(4-tert-butylphenyl)-5-chloro-7-(4-methyl-1-piperidinyl)[1,2,4]triazolo[1,5-
	alpyrimidine

10

15

20

25

### Example 14 5-chloro-6-(4-methoxyphenyl)-7-(4-methyl-1-piperidinyl)[1,2,4]triazolo[1,5a]pyrimidine Example 15 5-chloro-6-(4-methoxyphenyl)-7-(3-methyl-1-piperidinyl)[1,2,4]triazolo[1,5a]pyrimidine Example 16 6-(4-bromophenyl)-5-chloro-7-(3-methyl-1-piperidinyl)[1,2,4]triazolo[1,5a]pyrimidine Example 17 5-chloro-6-(3,4-difluorophenyl)-7-(4-methyl-1-piperidinyl)[1,2,4]triazolo[1,5a]pyrimidine Example 18 5-chloro-6-(2,6-dichlorophenyl)-7-(2-methyl-1-pyrrolidinyl)[1,2,4]triazolo[1,5-<u>alpyrimidine</u> Example 19 5-chloro-6-(2-chlorophenyl)-7-(2-methyl-1-pyrrolidinyl)[1,2,4]triazolo[1,5a]pyrimidine Example 20 7-(1-azepanyl)-5-chloro-6-(3-chloro-4-methoxyphenyl)[1,2,4]triazolo[1,5-

a]pyrimidine

## <u>Example 21</u> <u>5-chloro-6-(3-chloro-4-methoxyphenyl)-7-(4-methyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine</u>

5	Example 22
	5-chloro-6-(3-chloro-4-methoxyphenyl)-7-(2-methyl-1-
	piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine
	Example 23
10	6-(4-tert-butylphenyl)-5-chloro-7-(2-methyl-1-piperidinyl)[1,2,4]triazolo[1,5-
	a]pyrimidine
	Example 24
	5-chloro-7-(2-methyl-1-piperidinyl)-6-[3-
15	(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidine
	Example 25
	Diethyl 2-[6-(2,6-difluorophenyl)-5-ethoxy[1,2,4]triazolo[1,5-a]pyrimidin-7-
	<u>yl]malonate</u>
20	
	Example 26
	7-(azepanyl)-5-chloro-6-{2-chloro-6-nitrophenyl}[1,2,4}triazolo[1,5-a]pyrimidine
	Example 27
25	5-chloro-6-(2-chloro-6-fluorophenyl)-N-ethyl-N-(2-methyl-2-
	propenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
	Example 28
	5-chloro-6-(2-chloro-6-fluorophenyl)-N-(2,2,2- trifluoroethyl)[1,2,4]triazolo[1,5-

a]pyrimidin-7-amine

15

20

### Example 29

### 5-chloro-6-(2-chloro-6-fluorophenyl)-N-[(2,2-dichlorocyclopropyl)methyl]-N-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine

5	Example 30
	1-[5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]-3-
	piperidinol

## Example 31 N-bicyclo[2.2.1]hept-2-yl-5-chloro-6-(3-chloro-4-methoxyphenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine

## <u>Example 32</u> <u>5-chloro-6-(2,5-difluorophenyl)-N-dodecyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine</u>

## Example 33 5-chloro-7-(4-methyl-1-piperidinyl)-6-(2,3,6- trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine

Example 34

N-[5-chloro-6-(2,3,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]-Nisopropylamine

25 <u>Example 35</u> 5-chloro-N-ethyl-N-(2-methyl-2-propenyl)-6-(2,3,6trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine

## Example 36 N-allyl-5-chloro-6-(2-chloro-6-fluorophenyl)-N-(2-methyl-2-propenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine

### Example 37 5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine

#### Example 38

5 <u>5-chloro-6-(3-chloro-4-methoxyphenyl)-N-cycloheptyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine</u>

#### Example 39

5-chloro-6-(3-chloro-4-methoxyphenyl)-7-(3,3-dimethyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine

Example 40

5-chloro-N-(3-chloropropyl)-N-methyl-6-(2,3,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine

15

10

Example 41
7-(1-azocanvl)-5-chloro-6-(2,3,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine

#### Example 42

20

5-chloro-6-(2,6-difluorophenyl)-7-(3,6-dihydro-1(2H)-pyridinyl)[1,2,4]triazolo[1,5-a]pyrimidine

#### Example 43

7-(1-azocanyl)-5-chloro-6-(2,6-difluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine

25

#### Example 44

5-methoxy-6-(2-chloro-6-fluorophenyl)-7-(4-methyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine

20

## <u>Example 45</u> [5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]methanol

5	Example 46
	1-[5-chloro-6-(2,6-difluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]-4-
	<u>piperidinol</u>
	Example 47
10	5-chloro-7-(4-chloro-1-piperidinyl)-6-(2,6-difluorophenyl)[1,2,4]triazolo[1,5-

<u>Example 48</u> 5-chloro-7-(4-thiomorpholinyl)-6-(2,3,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine

a]pyrimidine

<u>Example 49</u>
<u>5-chloro-6-(2,6-difluorophenyl)-7-(2,4-dimethyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine</u>

Example 50
7-(4-methyl-1-piperidinyl)-5-amino-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine

25 <u>Example 51</u>

5-chloro-6-(2,6-difluorophenyl)-7-(2,5-dihydro-1H-pyrrol-1-yl)[1,2,4]triazolo[1,5-a]pyrimidine

Example 52

5-chloro-6-(2-chloro-6-fluorophenyl)-7-(2,5-dimethyl-2,5-dihydro-1H-pyrrol-1-yl)[1,2,4]triazolo[1,5-a]pyrimidine

### <u>Example 53</u> <u>5-chloro-6-(2-chloro-6-fluorophenyl)-7-(2-ethyl-1H-imidazol-1-yl)[1,2,4]triazolo[1,5-a]pyrimidine</u>

5	Example 54
	7-(4-bromo-1-piperidinyl)-5-chloro-6-(2-chloro-6-
	fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine
	Example <u>55</u>
10	5-chloro-6-(2-methylphenyl)-7-(4-thiomorpholinyl)[1,2,4]triazolo[1,5-
10	a]pyrimidine
	ајрунтишто
	Example 56
	6-(2-bromophenyl)-N-(sec-butyl)-5-chloro[1,2,4]triazolo[1,5-a]pyrimidin-7
15	<u>amine</u>
	Example 57
	5-chloro-N-ethyl-6-(4-methoxyphenyl)-N-(2-methyl-2-
	propenyl)[1,2,4]triazolo[1,5- a]pyrimidin-7-amine
20	
	Example 58
	5-chloro-6-(4-methoxyphenyl)-7-(4-thiomorpholinyl)[1,2,4]triazolo[1,5-
	<u>a]pyrimidine</u>
05	Example 59
25	•
	5-chloro-7-(4-chloro-1-piperidinyl)-6-[2- (trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidine
	(trinuorometriyi)prienyiji 1,2,4 julazoloj 1,5-ajpyrimaine
	Example 60
30	5-chloro-6-(2-chloro-6-fluorophenyl)-7-[4-(trifluoromethyl)-1-
	piperidinyl][1,2,4]triazolo[1,5-a]pyrimidine

<u>Example 61</u>
7-(4-bromo-1-piperidinyl)-5-chloro-6-(2,6-difluorophenyl)[1,2,4]triazolo[1,5-
a]pyrimidine
Example 62
7-(4-bromo-1-piperidinyl)-5-chloro-6-(2-chlorophenyl)[1,2,4]triazolo[1,5-
<u>a]pyrimidine</u>
Example 63
5-chloro-N-ethyl-N-(2-methyl-2-propenyl)-6-(2,4,6-
trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
Evample 64
Example 64  5. 11 Niconard C (0.4 C triffugraph and 14.2 Altriagolo 14.5 alphyrimidin 7.
5-chloro-N-isopropyl-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5- a]pyrimidin-7-
<u>amine</u>
Example 65
5-chloro-7-(4-thiomorpholinyl)-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-
a]pyrimidine
Example 66
7-(1-azepanyl)-5-chloro-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-
a]pyrimidine
Example 67
5-chloro-6-(2-chloro-6-fluorophenyl)-7-[2-(1-pyrrolidinyl)-1-cyclopenten-1-
yl][1,2,4]triazolo[1,5-a]pyrimidine
Example 68
5-chloro-7-(4-isopropyl-1-piperidinyl)-6-(4-methoxyphenyl)[1,2,4]triazolo[1,5-

a]pyrimidine

10

15

20

25

30

### Example 69 5-chloro-7-(2,4-dimethyl-1-piperidinyl)-6-(4-methoxyphenyl)[1,2,4]triazolo[1,5a]pyrimidine Example 70 5-chloro-7-[ethyl(2-methyl-2-propenyl)amino]-6-{4nitrophenyl}[1,2,4]triazolo[1,5-a]pyrimidine Example 71 7-(1-azepanyl)-5-chloro-6-{4-nitrophenyl}[1,2,4]triazolo[1,5-a]pyrimidine Example 72 N-bicyclo[2.2.1]hept-2-yl-5-chloro-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5a]pyrimidin-7-amine Example 73 5-chloro-6-(2,6-difluorophenyl)-N-(2,2,2-trifluoroethyl)[1,2,4]triazolo[1,5alpyrimidin-7-amine Example 74 5-chloro-6-(2-chlorophenyl)-N-(2,2,2-trifluoroethyl)[1,2,4]triazolo[1,5a]pyrimidin-7-amine Example 75 5-chloro-6-(2-chloro-6-fluorobenzyl)-7-tetrahydro-2-furanyl[1,2,4]triazolo[1,5a]pyrimidine

Example 76

7-(allylsulfanyl)-5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine

### 5-chloro-N-ethyl-6-mesityl-N-(2-methyl-2-propenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine

5

#### Example 78

## 5-chloro-N-ethyl-6-(2-methoxyphenyl)-N-(2-methyl-2-propenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine

10

#### Example 79

5-chloro-6-(2-chloro-6-fluorophenyl)-N-hexyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine

#### Example 80

15

20

5-chloro-7-(4-methyl-1-piperidinyl)-6-[4-

(methylsulfanyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidine

#### Example 81

5-chloro-N-ethyl-N-(2-methyl-2-propenyl)-6-[4-

(methylsulfanyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine

#### Example 82

N-(sec-butyl)-5-chloro-6-[4-(methylsulfanyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine

25

#### Example 83

5-chloro-6-[4-(methylsulfanyl)phenyl]-7-(4-thiomorpholinyl)[1,2,4]triazolo[1,5-a]pyrimidine

### 5-chloro-6-[2,6-dichloro-4-(trifluoromethyl)phenyl]-7-(4-methyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine

_

#### Example 85

### 7-(1-azepanyl)-5-chloro-6-[2,6-dichloro-4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidine

1	Ω

#### Example 86

### 5-chloro-6-(2-chloro-6-fluorophenyl)-7-[(2,2,2-trifluoroethyl)sulfanyl][1,2,4]triazolo[1,5-a]pyrimidine

### 15

20

#### Example 87

5-chloro-6-(2-chloro-6-fluorophenyl)-7-(4,4-dimethyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine

#### Example 88

5-chloro-6-[2,6-dichloro-4-(trifluoromethyl)phenyl]-N-ethyl-N-(2-methyl-2-propenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine

#### Example 89

5-chloro-6-[2,6-dichloro-4-(trifluoromethyl)phenyl]-7-(4-thiomorpholinyl)[1,2,4]triazolo[1,5-a]pyrimidine

#### 25

#### Example 90

5-chloro-6-(3,5-difluorophenyl)-7-(4-methyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine

20

25

## <u>Example 91</u> <u>5-chloro-6-(2-chloro-6-fluorophenyl)-7-(isopropylsulfanyl)[1,2,4]triazolo[1,5-a]pyrimidine</u>

5	Example 92
	5-chloro-6-(2-chloro-6-fluorophenyl)-7-tetrahydro-2-furanyl[1,2,4]triazolo[1,5-
	<u>a]pyrimidine</u>
	Example 93
	4-[5-chloro-7-(4-methyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidin-6-yl]aniline
0	Example 94
	N-{4-[5-chloro-7-(4-methyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidin-6-
	yl]phenyl}acetamide
	Example 95

[5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]methyl acetate

<u>Example 96</u>
<u>5-chloro-6-(2-chloro-6-fluorophenyl)-7-(chloromethyl)[1,2,4]triazolo[1,5-a]pyrimidine</u>

Example 97
diethyl 2-[6-(2-chloro-6-fluorophenyl)-7-(4-methyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidin-5-yl]malonate

Example 98

7-(1-azepanylmethyl)-5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine

# <u>Example 99</u> N-allyl-5-chloro-6-(2-chloro-6-fluorophenyl)-N-hexyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine

5	Example 100
	5-chloro-7-(4-methyl-1-piperidinyl)-6-[4-
	(trifluoromethoxy)phenyl][1,2,4]triazolo[1,5-a]pyrimidine
	Example 101
10	5-chloro-7-(4-methyl-1-piperidinyl)-6-(4-phenoxyphenyl)[1,2,4]triazolo[1,5-
	<u>a]pyrimidine</u>
	Example 102
	5-chloro-6-(2-chloro-6-fluorophenyl)-N-(cyclopropylmethyl)-N-
15	propyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
	Example 103
	5-chloro-7-(2-methyl-1-piperidinyl)-6-(4-phenoxyphenyl)[1,2,4]triazolo[1,5-
	a]pyrimidine
20	
	Example 104
	5-chloro-6-{2-chloro-4-nitrophenyl}-7-(4-methyl-1-
	piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine
25	Example 105
	5-chloro-6-(4-chloro-2,3,5,6-tetrafluorophenyl)-N-
	cyclopentyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
	Example 106
30	4-[5-chloro-2-methyl-7-(4-methyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidin-
	6-vII-N.N-dimethylaniline

# Example 107 6-(2-chloro-6-fluorophenyl)-5-methyl-7-(4-methyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine

5	Example 108
	5-chloro-6-(2-chloro-6-fluorophenyl)-7-[2-(1-pyrrolidinyl)-1-cyclohexen-1-
	yl][1,2,4]triazolo[1,5-a]pyrimidine
	Example 109
10	5-chloro-6-(2-chloro-6-fluorophenyl)-7-(methoxymethyl)[1,2,4]triazolo[1,5-
	a]pyrimidine
	Example 110
	5-chloro-6-{2-chloro-4-nitrophenyl}-7-[ethyl(2-methyl-2-
15	propenyl)amino][1,2,4]triazolo[1,5-a]pyrimidine
	Example 111
	5-bromo-6-(2-chloro-6-fluorophenyl)-7-(isopropylsulfanyl)[1,2,4]triazolo[1,5-
	<u>a]pyrimidine</u>
20	
	Example 112
	5-chloro-N-cyclopentyl-6-(4-ethoxy-2,3,5,6-
	tetrafluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
25	Example 113
	5-chloro-N-methyl-N-(2-methyl-2-propenyl)-6-(2,4,6-
	trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
	Example 114
30	4-bromo-1-[5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-
	7-yl]butyl acetate

## <u>diethyl 2-allyl-2-{[5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]oxy}malonate</u>

5	Example 116
	6-(2-chloro-6-fluorophenyl)-N-ethyl-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-
	<u>amine</u>
	Example 117
10	N-butyl-5-chloro-N-ethyl-6-(2,3,4,5,6-pentafluorophenyl)[1,2,4]triazolo[1,5-
	a]pyrimidin-7-amine
	Example 118
	6-(2-chloro-6-fluorophenyl)-5-(difluoromethoxy)-7-(4-methyl-1-
15	piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine
	Example 119
	5-chloro-6-(2-chloro-6-fluorophenyl)-7-[(4-
	chlorophenyl)sulfanyl][1,2,4]triazolo[1,5-a]pyrimidine
20	
	Example 120
	5-chloro-6-(2-chloro-6-fluorophenyl)-7-[(2-
	methoxyphenyl)sulfanyl][1,2,4]triazolo[1,5-a]pyrimidine
25	Example 121
	5-chloro-6-(2-chloro-6-fluorophenyl)-N-(1,2,2-
	trimethylpropyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
	Example 122
30	5-chloro-6-(2,3,4,5,6-pentafluorophenyl)-N-(1,2,2-
-	trimethylpropyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
	unitoury propyry 1,2, rendeduction to dispyrimani i dimino

<del>-</del>152-

# <u>Example 123</u> 5-chloro-6-(2,4,6-trifluorophenyl)-N-(1,2,2-trimethylpropyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine

5	Example 124
	5-chloro-6-(4-fluorophenyl)-N-(1,2,2- trimethylpropyl)[1,2,4]triazolo[1,5-
	a]pyrimidin-7-amine
	Example 125
10	5,7-bis(4-methyl-1-piperidinyl)-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-
	<u>a]pyrimidine</u>
	<b>-</b> 1 400
	Example 126
	5-chloro-6-(2-methylphenyl)-N-(1,2,2-trimethylpropyl)[1,2,4]triazolo[1,5-
15	<u>a]pyrimidin-7-amine</u>
	Example 127
	5-chloro-6-(2,4,5-trifluorophenyl)-N-(1,2,2-trimethylpropyl)[1,2,4]triazolo[1,5
	a]pyrimidin-7-amine
20	аруптан тапто
20	Example 128
	6-(2-bromophenyl)-5-chloro-N-(1,2,2-trimethylpropyl)[1,2,4]triazolo[1,5-
	a]pyrimidin-7-amine
25	Example 129
	5-chloro-N-isobutyl-N-(2,2,2-trifluoroethyl)-6-(2,4,6-
	trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
	Example 130
30	5-chloro-N-isobutyl-6-(2-methylphenyl)-N-(2,2,2-
	trifluoroethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine

# <u>Example 131</u> <u>5-chloro-6-(2-chloro-6-fluorophenyl)-N-(2,2,2-trifluoro-1-methylethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine</u>

5	Example 132
	5-chloro-6-(2,6-difluorophenyl)-N-(2,2,2-trifluoro-1-
	methylethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
	Example 133
10	5-chloro-N-(2,2,2-trifluoro-1-methylethyl)-6-(2,4,6-
	trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
	Example 134
	N-allyl-5-chloro-N-isobutyl-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-
15	a]pyrimidin-7-amine
	Example 135
	5-chloro-N-(1,2-dimethylpropyl)-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5
	a]pyrimidin-7-amine
20	
	Example 136
	5-chloro-N-isopropyl-N-methyl-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-
	<u>a]pyrimidin-7-amine</u>
25	Example 137
	5-chloro-N-isopropyl-N-(2,2,2-trifluoroethyl)-6-(2,4,6-

trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine

10

15

20

25

### Example 138 7-butyl-5-chloro-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine

5-chloro-N-(1-phenylethyl)-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-
alovrimidin-7-amine

Example 139

### <u>Example 140</u> 5-chloro-6-(2-chlorophenyl)-N-(2,2,2-trifluoro-1-methylethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine

## Example 141 5-chloro-N-ethyl-N-isobutyl-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine

<u>Example 142</u> <u>5-chloro-6-(2-chloro-6-fluorophenyl)-7-hexyl[1,2,4]triazolo[1,5-a]pyrimidine</u>

Example 143

5-chloro-6-(2-methylphenyl)-N,N-bis(2,2,2-trifluoroethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine

## Example 144 5-chloro-N-cyclopentyl-N-methyl-6-(2,3,4,5,6pentafluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine

Example 145
7-butyl-5-chloro-6-(2,6-difluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine

# <u>Example 146</u> <u>5-chloro-N-(1,2-dimethylpropyl)-N-methyl-6-(2,3,4,5,6-pentafluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine</u>

5	Example 147
	5-chloro-6-(2-chloro-6-fluorophenyl)-7-phenyl[1,2,4]triazolo[1,5-a]pyrimidine
	Example 148
	5-chloro-6-(2-chloro-6-fluorophenyl)-7-(2-methylpropanyl)[1,2,4]triazolo[1,5-
10	<u>a]pyrimidine</u>
	Example 149
	5-chloro-6-(2-chloro-6-fluorophenyl)-7-pentyl[1,2,4]triazolo[1,5-a]pyrimidine
15	Example 150
	5-chloro-N-(1,2-dimethylpropyl)-N-methyl-6-(2,4,6-
	trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
	Example 151
20	5-chloro-6-(2-chloro-6-fluorophenyl)-7-cyclohexyl[1,2,4]triazolo[1,5-
	<u>a]pyrimidine</u>
	Example 152
	5-chloro-6-(2-bromo-5-chlorophenyl)-N-(2,2,2-trifluoro-1-
25	methylethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
	Example 153
	5-chloro-6-(2-chloro-6-fluorophenyl)-7-(3,3,3-trifluoropropyl)[1,2,4]triazolo[1,5-
	<u>a]pyrimidine</u>

# <u>Example 154</u> <u>5-chloro-6-(2-chloro-6-fluorophenyl)-7-(3-methylphenyl)[1,2,4]triazolo[1,5-a]pyrimidine</u>

5	Example 155
	[5-chloro-6-(2,4,6-trifluorophenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]-(1-p-tolyl-
	ethyl)-amine
	Example 156
10	5-chloro-6-(2,4,6-trifluoro-phenyl)-7-cyclohexyl[1,2,4]triazolo[1,5-a]pyrimidine
	Example 157
	5-chloro-7-cyclohexyl-6-(2,3,4,5,6-pentafluorophenyl)[1,2,4]triazolo[1,5-
	a]pyrimidine
15	
15	Evennle 159
	<u>Example 158</u>
	5-chloro-6-(2-chloro-6-fluorophenyl)-7-(4,4-difluoro-1-
	piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine
20	Example 159
	7-(bicyclo[2.2.1]hept-2-ylamino)-5-chloro-6-{2-fluoro-4-
	nitrophenyl}[1,2,4]triazolo[1,5-a]pyrimidine
	Example 160
25	5-chloro-6-{2-fluoro-4-nitrophenyl}-7-(4-methyl-1-piperidinyl)[1,2,4]triazolo[1,5-
	<u>a]pyrimidine</u>

<u>Example 161</u>

<u>5-(methylsulfanyl)-6-(2-chloro-6-fluorophenyl)-7-cyclohexyl[1,2,4]triazolo[1,5-a]pyrimidine</u>

### Example 162

### [5-chloro-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl] (2,2,2trifluoro-1-phenylethyl)-amine

5	Example 163
	5-chloro-N-[1-(trifluoromethyl)propyl]-6-(2,4,6-
	trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
	Example 164
10	5-bromo-6-(2-chloro-6-fluorophenyl)-7-cyclohexyl[1,2,4]triazolo[1,5-
	<u>a]pyrimidine</u>
	Example 165
	6-(2-chloro-6-fluorophenyl)-7-cyclohexyl[1,2,4]triazolo[1,5-a]pyrimidin-5-amine
15	
	Example 166
	[5-chloro-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]-(2-methyl-
	1-trifluoromethyl-propyl)amine
20	Example 167
	5-chloro-7-(3-cyclohexen-1-yl)-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-
	<u>a]pyrimidine</u>
	Example 168
25	5-chloro-7-(1-cyclohexen-1-yl)-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-
	<u>a]pyrimidine</u>
	Example 169
	5-chloro-N-[(1R)-2,2,2-trifluoro-1-methylethyl]-6-(2,4,6-
30	trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine

# Example 170 5-chloro-N-[(1R)-2,2,2-trifluoro-1-methylethyl]-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine

5	Example 171
	6-(2,4-difluorophenyl)-5-chloro-N-(2,2,2-trifluoro-1-
	methylethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
	Example 172
10	5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-(4-methyl-1-
	piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine
	Evernle 179
	Example 173
	5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-N-(2,2,2-trifluoro-1-
15	methylethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
	Example 174
	5-chloro-7-cyclohexyl-6-(2,6-difluoro-4-methoxyphenyl)[1,2,4]triazolo[1,5-
	<u>a pyrimidine</u>
20	
	Example 175
•	5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-N-[(1S)-2,2,2-trifluoro-1-
	methylethyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine
25	Example 176
	7-cyclohexyl-6-(2,6-difluoro-4-methoxyphenyl)-5-methoxy[1,2,4]triazolo[1,5
	<u>a]pyrimidine</u>
	Example 177
30	5-chloro-7-(4-fluorocyclohexyl)-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-
	a]pyrimidine

### 5-chloro-6-(2,6-dichloro-4-fluorophenyl)-7-(3,3,3trifluoropropyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine

5	Example 179			
	N-(sec-butyl)-5-chloro-6-(2,6-dichloro-4-fluorophenyl)[1,2,4]triazolo[1,5-			
	a]pyrimidin-7-amine			
	Example 180			
10	4-{5-chloro-7-[(2,2,2-trifluoro-1-methylethyl)amino][1,2,4]triazolo[1,5-			
	a]pyrimidin-6-yl}-3,6-difluorophenol			
	Example 181			
	5-chloro-7-(3-cyclohexen-1-yl)-6-(2,6-difluoro-4-			
15	methoxyphenyl)[1,2,4]triazolo[1,5-a]pyrimidine			
	Example 182			
	5-chloro-6-(2,6-difluoro-4-methoxyphenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-			
	<u>amine</u>			
20				
	Example 183			
	5-chloro-N-cyclopentyl-6-(2,6-difluoro-4-methoxyphenyl)[1,2,4]triazolo[1,5-			
	<u>a]pyrimidin-7-amine</u>			
25	Example 184			
23	5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-(3,6-dihydro-1(2H)-			
	pyridinyl)[1,2,4]triazolo[1,5-a]pyrimidine			
	<u> </u>			
	Example 185			
30	5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-(4-			
	thiomorpholinyl)[1,2,4]triazolo[1,5-a]pyrimidine			

**-**160-

## Example 186 7-(1-azepanyl)-5-chloro-6-(2,6-difluoro-4-methoxyphenyl)[1,2,4]triazolo[1,5-a]pyrimidine

5	Example 187
	5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-N-(1,2,2-
	trimethylpropyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
	Example 188
10	5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-N-ethyl-N-(2-methyl-2-
	propenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
	Example 189
	5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-(4-
15	fluorocyclohexyl)[1,2,4]triazolo[1,5-a]pyrimidine
	Example 190
	6-(4-{5-chloro-7-[(2,2,2-trifluoro-1-methylethyl)amino][1,2,4]triazolo[1,5-
	a]pyrimidin-6-yl}-3,5-difluorophenoxy)hexanoic acid
20	appyrimant o yij o,o amaorop, onoxy j. oxantos acta
20	Example 191
	2,6-difluoro-4-(2-fluoroethoxy)phenyl]-N-(2,2,2-trifluoro-1-
	methylethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
05	Example 192
25	<del></del>
	5-chloro-N-isopropyl-6-{2-[(trifluoromethyl)sulfanyl]phenyl}[1,2,4]triazolo[1,5
	a]pyrimidin-7-amine
	Example 193
30	5-chloro-N-[4-(trifluoromethyl)phenyl]-6-(2,4,6-

trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine

# <u>Example 194</u> <u>5-chloro-N-(4,4,4-trifluoro-2-methylbutyl)-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine</u>

5	Example 195
	5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-(3-methyl-3-
	butenyl)[1,2,4]triazolo[1,5-a]pyrimidine
	Example 196
10	5-chloro-6-(2,6-difluoro-4-methoxyphenyl)-7-isobutyl[1,2,4]triazolo[1,5-
	<u>a]pyrimidine</u>
	Example 197
	7-cyclopentyl-6-(2,6-difluoro-4-methoxyphenyl)-5-methoxy[1,2,4]triazolo[1,5
15	<u>a]pyrimidine</u>
	Example 198
	5-chloro-6-(2-thienyl)-N-[(1R)-2,2,2-trifluoro-1-methylethyl[1,2,4]triazolo[1,5-
	a]pyrimidin-7-amine
20	
	<u>Example 199</u>
	4-(5-chloro-7-(2,2,2-trifluoro-1-methyl-ethylamino)[1,2,4]triazolo[1,5-
	a]pyrimidin-6-yl]-3,5-difluoro-phenol
0.5	Example 200
25	Example 200  (5 ablazo 6.13.6 diffuero 4.43.3.3 trifluero etboya) phonyll [4.3.4]triozolo[4.5.4]
	{5-chloro-6-[2,6-difluoro-4-(2,2,2-trifluoro-ethoxy)-phenyl]-[1,2,4]triazolo[1,5-
	a]pyrimidin-7-yl}-(2,2,2-trifluoro-1-methyl-ethyl)amine
	Example 201
30	5-chloro-6-{2,6-difluoro-4-(methoxyphenyl)-N-(2,2,2-trifluoro-1-
30	<u>5-611010-0-12,0-41114010-4-(metroxypherryr)-14-(2,2,2,2-trind010-1-</u>

methylethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine

## (5-chloro-6-{4-[2-(2-ethoxyethoxy]-ethoxy]-2,6-difluoro-phenyl}[1,2,4]triazolo[1,5-a]pyrimidin-7-yl-)-(2,2,2-trifluoro-1-methylethyl)amine

5

#### Example 203

(5-chloro-6-{2,6-difluoro-4-[2-(2-methoxy-ethoxy)ethoxy]-phenyl}-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl-)-(2,2,2-trifluoro-1-methylethyl)amine

10

#### Example 204

5-chloro-6-[2,6-difluoro-4-(3-furan-3-ylmethoxy)phenyl[1,2,4]triazolo[1,5-a]pyrimidin-7-yl}-N-(2,2,2-trifluoro-1-methylethyl)amine

Example 205

15

5-chloro-6-(2,5-difluoro-4-methoxyphenyl)-N-(1,2,2-trimethylpropyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine

#### Example 206

7-cyclohexyl-6-[2,6-difluoro-4-(2-methoxyethoxy)phenyl]-5methoxy[1,2,4]triazolo[1,5-a]pyrimidine

20

#### Example 207

5-chloro-6-(2-fluoro-4-methoxy-6-chlorophenyl)-N-(2,2,2-trifluoro-1-methylethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine

25

#### Example 208

5-chloro-6-[2,6-difluoro-4-(2-fluoroethoxy)phenyl]-N-ethyl-N-(2-methyl-2-propenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine

## $\underline{2\text{-}[2\text{-}(4\text{-}\{5\text{-}chloro\text{-}7\text{-}[(2,2,2\text{-}trifluoro\text{-}1\text{-}methylethyl)amino}][1,2,4]triazolo[1,5\text{-}a]pyrimidin-6\text{-}yl}\text{-}3,5\text{-}difluorophenoxy)ethoxy]ethanol}$

5	Example 210
	5-chloro-6-(2,3-difluoro-4-methoxyphenyl)-N-(2,2,2-trifluoro-1-
	methylethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
	Example 211
10	5-chloro-6-{4-(2-fluoroethoxy)-2,6-difluorphenyl}-N-(2,2,2-trifluoro-1-
	methylethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
	Example 212
	5-chloro-N-(4-chlorobenzyl)-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5
15	a]pyrimidin-7-amine
	Example 213
	5-chloro-6-(2-chloro-6-fluorophenyl)-7-[4-(2-pytidinyl)-1-
	piperazinyl][1,2,4]triazolo[1,5-a]pyrimidine
20	
	Example 214
	5-chloro-6-(2-chloro-6-fluorophenyl)-N-(1-ethylpentyl)[1,2,4]triazolo[1,5-
	a]pyrimidin-7-amine
25	Example 215
	5-chloro-6-(2-chloro-6-fluorophenyl)-7-[4-(2-chlorophenyl)-1-
	piperazinyl][1,2,4]triazolo[1,5-a]pyrimidine
	Example 216
30	5-chloro-6-(2-chloro-6-fluorophenyl)-7-[4-(4-methoxyphenyl)-3-methyl-1-

piperazinyl][1,2,4]triazolo[1,5-a]pyrimidine

## 5-chloro-N-cyclopentyl-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine

5	Example 218
	5-chloro-7-phenoxy-6-(4-methoxy-phenyl)[1,2,4]triazolo[1,5-a]pyrimidine
10	Example 219 5-chloro-N-cyclopentyl-6-(4-methylphenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7- amine
	Example 220 5,7-diphenoxy-6-(4-methoxyphenyl)[1,2,4]triazolo[1,5-a]pyrimidine
15	Example 221  5-chloro-N-cyclopentyl-6-(2-chlorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7- amine
20	Example 222  5-chloro-N,N-diethyl-6-[4-methoxyphenyl][1,2,4]triazolo[1,5-a]pyrimidin-7- amine
25	Example 223  5-chloro-N,N-diethyl-6-[2,4-dichlorophenyl][1,2,4]triazolo[1,5-a]pyrimidin-7- amine
	Example 224  N-bicyclo[2.2.1]hept-2-yl-5-chloro-6-(2,4-dichlorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine

## $\underline{5\text{-chloro-}6\text{-}(2\text{-chloro-}6\text{-fluorophenyl})\text{-}7\text{-}(1,4\text{-dioxa-}8\text{-}azaspiro[4.5]dec-}8\text{-}}\\ \underline{yl)[1,2,4]triazolo[1,5\text{-}a]pyrimidine}$

5	Example 226
	5-cyano-7-(4-methyl-1-piperidinyl)-6-(2-chloro-5-
	fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine
	Example 227
10	5-(methylsulfanyl)-7-(4-methyl-1-piperidinyl)-6-(2-chloro-6-
	fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine
	Example 228
	5-(methylsulfanyl)-7-(4-methyl-1-piperidinyl)-6-(2-chloro-5-
15	(methylsulfanyl)phenyl)[1,2,4]triazolo[1,5-a]pyrimidine
	Example 229
	5-chloro-7-(1,4-dioxa-8-azaspiro[4,5]dec-8-yl)-6-(4-
	methoxyphenyl)[1,2,4]triazolo[1,5-a]pyrimidine
20	
	Example 230
	5-chloro-N-ethyl-N-(2-methyl-2-propenyl)-6-(4-
	(methylsulfanyl)phenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
25	Example 231
	2-methyl-6,7-di-(4-methoxyphenyl)[1,2,4]triazolo[1,5-a]pyrimidine
	Example 232
	2-methyl-6-phenyl-7-(4-chlorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine
30	

### Example 233 2-trifluoromethyl-6-phenyl-7-(4-methoxyphenyl)[1,2,4]triazolo[1,5-a]pyrimidine

Exar	nn	ما	234
LXai	IID		204

5,7-diphenoxy-6-(2-methylpropyl)[1,2,4]triazolo[1,5-a]pyrimidine

#### Example 235

5-chloro-6-(3,4-difluorophenyl)-N-(isopropyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine

10

5

#### Example 236

5-bromo-6-(4-bromophenyl)-7-dimethylamino[1,2,4]triazolo[1,5-a]pyrimidine

#### Example 237

15

<u>5-bromo-6-(4-trifluoromethylphenyl)-7-dimethylamino[1,2,4]triazolo[1,5-a]pyrimidine</u>

#### Example 238

5-chloro-6-(3,4-difluorophenyl)-7-dimethylamino[1,2,4]triazolo[1,5-a]pyrimidine

20

#### Example 239

5-chloro-6-(4-trifluoromethylphenyl)-N-(ethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine

25

#### Example 240

7-(1-azepanyl)-5-chloro-6-(4-tert-butylphenyl)[1,2,4]triazolo[1,5-a]pyrimidine

#### Example 241

ethyl {[5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]amino}acetate

30

20

25

## <u>Example 242</u> <u>diethyl 5-chloro-6-(2,6-difluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-malonate</u>

5	Example 243			
	5-chloro-6-(2,5-difluorophenyl)-N-(3-methyl-2-butenyl)[1,2,4]triazolo[1,5-			
	a]pyrimidin-7-amine			

## 10 [5-chloro-6-(2-chloro-6-fluorophenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]acetic acid methyl ester

Example 244

# Example 245 5-chloro-6-(2,6-difluorophenyl)-7-(2-ethyl-1H-imidazol-1-yl)[1,2,4]triazolo[1,5-a]pyrimidine

## <u>Example 246</u> 5-chloro-N,N-diethyl-6-[4-(methylsulfanyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine

Example 247

ethyl [6-(2-chloro-6-fluorophenyl)-7-(4-methyl-1-piperidinyl)- [1,2,4]triazolo[1,5-a]pyrimidin-5-yl]acetate

Example 248

5-chloro-N-ethyl-N-(2-methyl-2-propenyl)-6-(4phenoxyphenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine

# Example 249 dimethyl 2-[5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin 7-yl]malonate -168-

## <u>diethyl 2-{[5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]oxy}-2-isobutylmalonate</u>

5	Example 251
	2-[5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]-1,3-
	cyclohexanedione

#### Example 252

2-[5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]cyclohexanone

#### Example 253

5-chloro-7-(3-nitro-4-methylanilino)-6-(2, 4, 6-trifluorophenyl)
[1,2,4]triazolo[1,5-a]pyrimidine

#### Example 254

7-cyclohexyl-6-[2,6-difluoro-4-(2-methoxyethoxy)phenyl]5-(2-methoxyethoxy)[1,2,4]triazolo[1,5-a]pyrimidine

20

25

10

15

#### Example 255

7-(3-bromophenyl)-2-ethyl-6-(4-methoxyphenyl)[1,2,4]triazolo[1,5-a]pyrimidine

#### Example 256

7-(3-bromophenyl)-6-(3-chlorophenyl)-2-ethyl[1,2,4]triazolo[1,5-a]pyrimidine

#### Example 257

7-(4-bromophenyl)-2-ethyl-6-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidine

### 5-chloro-6-(2-chloro-6-fluorophenyl)-N-(3,4,5-

trimethoxybenzyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine

5	Example 259
	7-(2-benzyl-4,5-dihydro-1H-imidazol-1-yl)-5-chloro-6-(2-chloro-6-
	fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine
	Example 260
10	N-4-[5-chloro-6-(2-chloro-6-fluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl-
	N,N-1-diethyl-1,4-pentanediamine
	Example 261
	5-chloro-N-(3-methyl-2-butenyl)-6-phenyl[1,2,4]triazolo[1,5-a]pyrimidin-7-
15	<u>amine</u>
	Example 262
	5-dimethylamino-6-phenyl-N-cyclopentyl[1,2,4]triazolo[1,5-a]pyrimidin-7-
	<u>amine</u>
20	
	Example 263
	5-chloro-7-[(2-furylmethyl)sulfanyl]-6-(4-methoxyphenyl)[1,2,4]triazolo[1,5-
	<u>a]pyrimidine</u>
25	Example 264
	6-[1,1'-biphenyl]-4-yl-5-chloro-N-cyclopentyl[1,2,4]triazolo[1,5-a]pyrimidin-7
	<u>amine</u>
	Example 265
30	6-[4-(benzyloxy)phenyl]-5-chloro-N-isopropyl[1,2,4]triazolo[1,5-a]pyrimidin-7

<u>amine</u>

## 5-chloro-N-[(2,2-dichlorocyclopropyl)methyl]-6-(3,4,5-trimethoxyphenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine

5	Example 267
	N-cyclopentyl-6-(2-fluorophenyl)-5-hydrazino[1,2,4]triazolo[1,5-a]pyrimidin-7-
	<u>amine</u>
	Example 268
10	5-chloro-N-ethyl-6-(2-methylphenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
	Example 269
	6-(4-tert-butylphenyl)-5-chloro-N-isopropyl[1,2,4]triazolo[1,5-a]pyrimidin-7-
	<u>amine</u>
15	
	Example 270
	5-chloro-6-[2,6-difluoro-4-[(3-methyl-2-butenyl)oxy]phenyl]-N-(2,2,2-trifluoro-1
	methylethyl)-l[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
••	Everyla 274
20	Example 271  5 ablara 6 13 6 diffuera 4 (4 preparulara) phanull N (3 3 3 trifluera 1
	5-chloro-6-[2,6-difluoro-4-(1-propenyloxy)phenyl]-N-(2,2,2-trifluoro-1-methylethyl)-I[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
	metriyletriyi)-i[1,2,4]triazolo[1,5-a]pyrimidiri-7-amine
	Example 272
25	5-chloro-N-(3-tricyclo[2.2.1.0 <sup>2,6</sup> ]hept-1-yl)-6-(2,4,6-
	trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
	Example 273
	5-azido-7-cyclohexyl-6-(2-fluoro-6-chlorophenyl) [1,2,4]triazolo[1,5-
30	alpyrimidine

#### Example 274

## 5-azido-6-[2-chloro-6-fluorophenyl]-7-(4-methyl-1-piperidinyl)[1,2,4]triazolo[1,5-a]pyrimidine

Example 275

2,5-dichloro-7-(4-methyl-1-piperidinyl)-6-[2-chloro-6-fluorophenyl][1,2,4]triazolo[1,5-a]pyrimidine